

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1407	tibolone or livial or liviella or boltin or (org adj OD14)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/03/25 09:11
L2	1407	tibolone or livial or liviella or boltin or "Org OD14"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/03/25 08:59
L3	1406	tibolone or livial or liviella or boltin	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/03/25 09:00
L4	1795386	starch or (potato adj starch) or (corn adj starch) or (wheat adj starch) or (modified starch) or (agglomerated adj starch) or (granulated adj starch)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/03/25 09:04
L5	459911	stabilizer or antioxidant or (chelator or (chelating adj agent))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/03/25 09:02
L6	67179	(ascorbyl adj palmitate) or "6-O-palmitoylascorbic acid" or "ascorbate-6-palmitate" or (vitamin adj2 palmitate) or "ascorbic acid-6-O-palmitate" or (ascorbyl adj stearate) or (ascorbyl adj monostearate) or (ascorbic adj acid adj stearate) or (sodium adj ascorbate) or (ascorbic adj acid) or (hybrin) or "L-ascorbic acid"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/03/25 09:03
L7	1795505	starch or (potato adj starch) or (corn adj starch) or (amylomaize adj starch) or (amylum) or keoflo or (wheat adj starch) or (modified starch) or (agglomerated adj starch) or (granulated adj starch)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/03/25 09:04
L8	121258	lactose	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/03/25 09:48

L9	2814	11 and 17 and (15 or 16)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/03/25 09:07
L10	187	11 and 17 and (15 or 16).ti,ab,clm.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/03/25 09:07
L11	234	tibolone or livial or liviella or (org adj OD14)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/03/25 09:12
L12	116	111 and 17 and (15 or 16)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/03/25 09:12
L13	20	111 and 17 and (15 or 16).ti,ab,clm.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/03/25 09:31
L14	1173	11 not 111	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/03/25 09:31
L15	2	(11 not 111).ti,ab,clm.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/03/25 09:31
L16	130354	lactose or disaccharide	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/03/25 09:49
L17	96	112 not 113	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/03/25 10:59
L18	101	111 and 17 and (15 or 16) and 116	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/03/25 10:59

L19	0	l18 not l12	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/03/25 10:59
L20	69	tibolone and starch and (ascorb\$)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/03/25 11:00
L21	0	l20 not l12	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/03/25 11:00
L22	13	("4473564" "4172132" "3423507" "4185101" "4159326").pn.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/03/25 11:01
S1	3	("6514958" "6399594").pn.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/03/25 08:58
S2	2	("6156343").pn.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/03/24 11:27
S3	2	("5916593").pn.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/03/24 11:12
S4	20	("4708874" "5178870" "5292520" "5441747" "5382434" "5662936" "6187339" "5916593" "5709881" "6063403").pn.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/03/24 11:12
S5	2	("4701450").pn.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/03/24 11:32
S6	0	ep-0389035-\$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/03/24 11:32

S7	2	ep-389035-\$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/03/24 11:37
S8	2	ep-613687-\$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/03/24 11:39
S9	2	ep-707848-\$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/03/24 11:43
S10	2	ep-503521-\$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/03/24 11:53
S11	2	wo-9506461-\$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/03/24 15:24
S12	228	tibolone	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/03/24 15:24
S13	161	S12 and starch	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/03/24 15:24
S14	9	(tibolone and starch and (antioxidant or chelat\$)).ti,ab,clm.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/03/24 15:25

Connecting via Winsock to STN

SEARCH NOTES

10/754, 732

3/25/05

Welcome to STN International! Enter x:x

LOGINID:sssptalar1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 01 New pricing for the Save Answers for SciFinder Wizard within
STN Express with Discover!
NEWS 4 OCT 28 KOREAPAT now available on STN
NEWS 5 NOV 30 PHAR reloaded with additional data
NEWS 6 DEC 01 LISA now available on STN
NEWS 7 DEC 09 12 databases to be removed from STN on December 31, 2004
NEWS 8 DEC 15 MEDLINE update schedule for December 2004
NEWS 9 DEC 17 ELCOM reloaded; updating to resume; current-awareness
alerts (SDIs) affected
NEWS 10 DEC 17 COMPUAB reloaded; updating to resume; current-awareness
alerts (SDIs) affected
NEWS 11 DEC 17 SOLIDSTATE reloaded; updating to resume; current-awareness
alerts (SDIs) affected
NEWS 12 DEC 17 CERAB reloaded; updating to resume; current-awareness
alerts (SDIs) affected
NEWS 13 DEC 17 THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
NEWS 14 DEC 30 EPFULL: New patent full text database to be available on STN
NEWS 15 DEC 30 CAPLUS - PATENT COVERAGE EXPANDED
NEWS 16 JAN 03 No connect-hour charges in EPFULL during January and
February 2005
NEWS 17 FEB 25 CA/CAPLUS - Russian Agency for Patents and Trademarks
(ROSPATENT) added to list of core patent offices covered
NEWS 18 FEB 10 STN Patent Forums to be held in March 2005
NEWS 19 FEB 16 STN User Update to be held in conjunction with the 229th ACS
National Meeting on March 13, 2005
NEWS 20 FEB 28 PATDPAFULL - New display fields provide for legal status
data from INPADOC
NEWS 21 FEB 28 BABS - Current-awareness alerts (SDIs) available
NEWS 22 FEB 28 MEDLINE/LMEDLINE reloaded
NEWS 23 MAR 02 GBFULL: New full-text patent database on STN
NEWS 24 MAR 03 REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS 25 MAR 03 MEDLINE file segment of TOXCENTER reloaded
NEWS 26 MAR 22 KOREAPAT now updated monthly; patent information enhanced
NEWS 27 MAR 22 Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS 28 MAR 22 PATDPASPC - New patent database available
NEWS 29 MAR 22 REGISTRY/ZREGISTRY enhanced with experimental property tags

NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:12:09 ON 25 MAR 2005

=> file registry

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 12:12:34 ON 25 MAR 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 MAR 2005 HIGHEST RN 847222-24-6

DICTIONARY FILE UPDATES: 24 MAR 2005 HIGHEST RN 847222-24-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> e tibolone/cn

E1	1	TIBO-R 86183/CN
E2	1	TIBOLON LIVIELLA/CN
E3	1 -->	TIBOLONE/CN
E4	1	TIBON/CN
E5	1	TIBONE/CN
E6	1	TIBOR 2.5-2.5/CN
E7	1	TIBOR 3-0.2/CN
E8	1	TIBOR 3-1/CN
E9	1	TIBOR 33/CN
E10	1	TIBOR 5-0.2/CN
E11	1	TIBOR 5-0.6/CN
E12	1	TIBOR 5-1/CN

=> s e2-e3

1 "TIBOLON LIVIELLA"/CN
1 TIBOLONE/CN
L1 2 ("TIBOLON LIVIELLA"/CN OR TIBOLONE/CN)

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

9.63

9.84

FILE 'CAPLUS' ENTERED AT 12:12:50 ON 25 MAR 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Mar 2005 VOL 142 ISS 14

FILE LAST UPDATED: 24 Mar 2005 (20050324/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l1

L2 386 L1

=> e tibolone/bi

E1 2 TIBOLIUM/BI
E2 3 TIBOLON/BI
E3 358 --> TIBOLONE/BI
E4 1 TIBOLONES/BI
E5 14 TIBON/BI
E6 1 TIBONCHINA/BI
E7 5 TIBOND/BI
E8 1 TIBONDS/BI
E9 1 TIBONE/BI
E10 1 TIBONI/BI
E11 1 TIBONUCLEOPROTEIN/BI
E12 4 TIBOOBURRA/BI

=> s e2-e4

3 TIBOLON/BI
358 TIBOLONE/BI
1 TIBOLONES/BI
358 TIBOLONE/BI
((TIBOLONE OR TIBOLONES)/BI)
1 TIBOLONES/BI
L3 359 (TIBOLON/BI OR TIBOLONE/BI OR TIBOLONES/BI)

=> e tibolone/ct

E#	FREQUENCY	AT	TERM
---	-----	--	----
E1	1	8	TIBICEN WINNEMANNA/CT

E2	0	1	TIBIELLA/CT
E3	0	-->	TIBOLONE/CT
E4	0	1	TIBOUCHIA/CT
E5	0	2	TIBOUCHIA BOURGAENA/CT
E6	1	13	TIBOUCHINA/CT
E7	0	2	TIBOUCHINA ALIENA/CT
E8	0	2	TIBOUCHINA GRANDIFLORA/CT
E9	4	8	TIBOUCHINA GRANULOSA/CT
E10	1	16	TIBOUCHINA LONGIFOLIA/CT
E11	2	8	TIBOUCHINA MULTIFLORA/CT
E12	12	8	TIBOUCHINA PULCHRA/CT

=> s 12 or 13

L4 430 L2 OR L3

=> s starch? or (potato starch?) or (corn starch?) or (amylomaize starch?) or
 amyllum? or keoflo? or (wheat starch?) or (modified starch?) or (agglomerated
 starch?) or (granulated starch?)

147702 STARCH?
 53947 POTATO
 35 POTATOS
 23309 POTATOES
 61080 POTATO
 (POTATO OR POTATOS OR POTATOES)
 147702 STARCH?
 8524 POTATO STARCH?
 (POTATO(W) STARCH?)
 112878 CORN
 365 CORNS
 113011 CORN
 (CORN OR CORNS)
 147702 STARCH?
 10943 CORN STARCH?
 (CORN(W) STARCH?)
 192 AMYLOMAIZE
 5 AMYLOMAIZES
 192 AMYLOMAIZE
 (AMYLOMAIZE OR AMYLOMAIZES)
 147702 STARCH?
 83 AMYLOMAIZE STARCH?
 (AMYLOMAIZE(W) STARCH?)
 114 AMYLUM?
 1 KEOFLO?
 116352 WHEAT
 2802 WHEATS
 116449 WHEAT
 (WHEAT OR WHEATS)
 147702 STARCH?
 3221 WHEAT STARCH?
 (WHEAT(W) STARCH?)
 511063 MODIFIED
 5 MODIFIEDS
 511066 MODIFIED
 (MODIFIED OR MODIFIEDS)
 147702 STARCH?
 2982 MODIFIED STARCH?
 (MODIFIED(W) STARCH?)
 7355 AGGLOMERATED
 147702 STARCH?
 5 AGGLOMERATED STARCH?
 (AGGLOMERATED(W) STARCH?)
 30570 GRANULATED
 147702 STARCH?
 15 GRANULATED STARCH?

(GRANULATED(W) STARCH?)
L5 147787 STARCH? OR (POTATO STARCH?) OR (CORN STARCH?) OR (AMYLOMAIZE
STARCH?) OR AMYLUM? OR KEOFLO? OR (WHEAT STARCH?) OR (MODIFIED
STARCH?) OR (AGGLOMERATED STARCH?) OR (GRANULATED STARCH?)

=> s stabilizer? or (stabilizing (W) (agent? or component? or compound?)) or
(antioxida?) or (chelate?)

105727 STABILIZER?
67792 STABILIZING
2 STABILIZINGS
67794 STABILIZING
(STABILIZING OR STABILIZINGS)
1461153 AGENT?
1121008 COMPONENT?
895362 COMPOUND?
1046326 COMPD
1610396 COMPDS
2282540 COMPD
(COMPD OR COMPDS)
2681023 COMPOUND?
(COMPOUND? OR COMPD)
16402 STABILIZING (W) (AGENT? OR COMPONENT? OR COMPOUND?)
125806 ANTIOXIDA?
2529 ANTIOXIDN
4 ANTIOXIDNS
2533 ANTIOXIDN
(ANTIOXIDN OR ANTIOXIDNS)
126860 ANTIOXIDA?
(ANTIOXIDA? OR ANTIOXIDN)
124446 CHELAT?

L6 348947 STABILIZER? OR (STABILIZING (W) (AGENT? OR COMPONENT? OR COMPOUN
D?)) OR (ANTIOXIDA?) OR (CHELAT?)

=> s (ascorbyl palmitate?) or "6-O-palmitoylascorbic acid" or
"ascorbate-6-palmitate" or "vitamin C palmitate" or "ascorbic-6-O-palmitate" or
(ascorbyl stearate?) or (sodium ascorbate?) or (ascorbic acid?) or hybrin? or
"L-ascorbic acid"

2114 ASCORBYL
23179 PALMITATE?
1124 ASCORBYL PALMITATE?
(ASCORBYL(W) PALMITATE?)
3538616 "6"
1444243 "O"
59 "PALMITOYLASCORBIC"
3954637 "ACID"
1469590 "ACIDS"
4430938 "ACID"
("ACID" OR "ACIDS")
11 "6-O-PALMITOYLASCORBIC ACID"
("6" (W) "O" (W) "PALMITOYLASCORBIC" (W) "ACID")
32312 "ASCORBATE"
592 "ASCORBATES"
32530 "ASCORBATE"
("ASCORBATE" OR "ASCORBATES")
3538616 "6"
22899 "PALMITATE"
479 "PALMITATES"
23167 "PALMITATE"
("PALMITATE" OR "PALMITATES")
4 "ASCORBATE-6-PALMITATE"
("ASCORBATE" (W) "6" (W) "PALMITATE")
179642 "VITAMIN"
50473 "VITAMINS"
198641 "VITAMIN"

```

("VITAMIN" OR "VITAMINS")
3283799 "C"
22899 "PALMITATE"
479 "PALMITATES"
23167 "PALMITATE"
("PALMITATE" OR "PALMITATES")
49 "VITAMIN C PALMITATE"
("VITAMIN" (W) "C" (W) "PALMITATE")
77508 "ASCORBIC"
3538616 "6"
1444243 "O"
22899 "PALMITATE"
479 "PALMITATES"
23167 "PALMITATE"
("PALMITATE" OR "PALMITATES")
0 "ASCORBIC-6-O-PALMITATE"
("ASCORBIC" (W) "6" (W) "O" (W) "PALMITATE")
2114 ASCORBYL
67574 STEARATE?
129 ASCORBYL STEARATE?
(ASCORBYL (W) STEARATE?)
970377 SODIUM
34 SODIUMS
970386 SODIUM
(SODIUM OR SODIUMS)
32534 ASCORBATE?
1596 SODIUM ASCORBATE?
(SODIUM (W) ASCORBATE?)
77508 ASCORBIC
4628709 ACID?
76833 ASCORBIC ACID?
(ASCORBIC (W) ACID?)
1 HYBRIN?
1395378 "L"
77508 "ASCORBIC"
3954637 "ACID"
1469590 "ACIDS"
4430938 "ACID"
("ACID" OR "ACIDS")
12316 "L-ASCORBIC ACID"
("L" (W) "ASCORBIC" (W) "ACID")
L7 78296 (ASCORBYL PALMITATE?) OR "6-O-PALMITOYLASCORBIC ACID" OR "ASCORB
ATE-6-PALMITATE" OR "VITAMIN C PALMITATE" OR "ASCORBIC-6-O-PALMI
TATE" OR (ASCORBYL STEARATE?) OR (SODIUM ASCORBATE?) OR (ASCORBI
C ACID?) OR HYBRIN? OR "L-ASCORBIC ACID"

```

=> s lactose or disaccharide?

```

47024 LACTOSE
90 LACTOSES
47032 LACTOSE
(LACTOSE OR LACTOSES)
16651 DISACCHARIDE?
L8 61648 LACTOSE OR DISACCHARIDE?

```

=> d his

(FILE 'HOME' ENTERED AT 12:12:09 ON 25 MAR 2005)

FILE 'REGISTRY' ENTERED AT 12:12:34 ON 25 MAR 2005

```

E TIBOLONE/CN
L1 2 S E2-E3

```

FILE 'CAPLUS' ENTERED AT 12:12:50 ON 25 MAR 2005

```

L2 386 S L1

```

L3 E TIBOLONE/BI
 359 S E2-E4
 E TIBOLONE/CT
 L4 430 S L2 OR L3
 L5 147787 S STARCH? OR (POTATO STARCH?) OR (CORN STARCH?) OR (AMYLOMAIZE
 L6 348947 S STABILIZER? OR (STABILIZING (W) (AGENT? OR COMPONENT? OR COMP
 L7 78296 S (ASCORBYL PALMITATE?) OR "6-O-PALMITOYLASCORBIC ACID" OR "ASC
 L8 61648 S LACTOSE OR DISACCHARIDE?

=> s 14 and 15 and (16 or 17)

L9 5 L4 AND L5 AND (L6 OR L7)

=> d 19 1-5 ibib ed abs

L9 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:1036906 CAPLUS

DOCUMENT NUMBER: 142:11606

TITLE: Immediate-release pharmaceutical dosage form
comprising a **tibolone** polymorph

INVENTOR(S): De Haan, Pieter

PATENT ASSIGNEE(S): Akzo Nobel N.V., Neth.

SOURCE: PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004103378	A1	20041202	WO 2004-EP50852	20040519
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2473718	AA	20041123	CA 2004-2473718	20040519
EP 1499278	A1	20050126	EP 2004-737220	20040519
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRIORITY APPLN. INFO.:			EP 2003-101500	A 20030523
			WO 2004-EP50852	W 20040519

ED Entered STN: 03 Dec 2004

AB An immediate-release pharmaceutical dosage form comprises a
tibolone polymorph and excipients, wherein the polymorph has a
 mean particle size as defined in the specification of below 22.8 µm in
 the dosage form. Thus, an immediate-release tablet formulation contained
tibolone 2.5, potato starch 10,
ascorbyl palmitate 0.2, Mg stearate 0.5, and lactose
 86.8 mg.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:453011 CAPLUS

DOCUMENT NUMBER: 140:429053

TITLE: Pharmaceutical tablets containing **tibolone**
 and a coating

INVENTOR(S): De Haan, Pieter; Van Lare, Cornelis Elisabeth Johannus
 PATENT ASSIGNEE(S): Akzo Nobel N.V., Neth.
 SOURCE: PCT Int. Appl., 20 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004045587	A1	20040603	WO 2003-EP50829	20031113
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			EP 2002-79920	A 20021120
			US 2002-427740P	P 20021120

ED Entered STN: 04 Jun 2004

AB The present invention relates to a stabilized pharmaceutical tablet comprising an amount of from 0.1 to 10% by weight of **tibolone** provided with a coating, such as a film coating, a sugar coating, a sugar film coating or a wrap coating. The invention further relates to the use of a coating for stabilizing a pharmaceutical tablet comprising **tibolone**. Preferably, the coating is a sugar coating or a sugar film coating. Preferably, the sugar comprises sucrose. These tablets were shown to have a lower amount of OM38, i.e. an isomerization degradation product of **tibolone**, after storage as compared to uncoated **tibolone** tablets. For example, a tablet was formulated containing **tibolone**, basic granulates (**starch**/lactose), **ascorbyl palmitate**, and Mg stearate and a film-coated with a composition containing hydroxypropyl Me cellulose, polyethylene glycol, titania, and talc, further coated with a composition containing arabic gum, saccharose, Ca carbonate, talc, titania, polyethylene glycol, glucose syrup, glycerol, and china clay.

L9 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:708947 CAPLUS

DOCUMENT NUMBER: 129:335779

TITLE: Stabilized **tibolone** compositions

INVENTOR(S): Haan De, Pieter; Rovers, Adrianus Cornelis Petrus; Lambregts-De Hurk, Theodora Antonia Maria; Zwinkels, Jocominus Antonius Maria; Morita, Ryoichi

PATENT ASSIGNEE(S): Akzo Nobel N.V., Neth.

SOURCE: PCT Int. Appl., 21 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9847517	A1	19981029	WO 1998-EP2361	19980420
W: AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, ID, IS, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, ML, MR, NE, SN, TD, TG

IL 123984	A1	20040927	IL 1998-123984	19980407
ZA 9803169	A	19981020	ZA 1998-3169	19980415
CA 2288070	AA	19981029	CA 1998-2288070	19980420
AU 9880146	A1	19981113	AU 1998-80146	19980420
AU 742037	B2	20011213		
EP 975348	A1	20000202	EP 1998-928214	19980420
EP 975348	B1	20041110		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI

TR 9902530	T2	20000522	TR 1999-9902530	19980420
BR 9809268	A	20000627	BR 1998-9268	19980420
NZ 338028	A	20011026	NZ 1998-338028	19980420
RU 2207133	C2	20030627	RU 1999-121407	19980420
AT 281836	E	20041115	AT 1998-928214	19980420
JP 10316573	A2	19981202	JP 1998-112312	19980422
TW 570798	B	20040111	TW 1998-87107211	19980511
US 2001005513	A1	20010628	US 1999-403139	19991014
US 6399594	B2	20020604		
NO 9905127	A	19991021	NO 1999-5127	19991021
MX 9909676	A	20000331	MX 1999-9676	19991021
US 6514958	B1	20030204	US 2002-117899	20020408
US 2003119801	A1	20030626	US 2002-303494	20021125
US 2004142030	A1	20040722	US 2004-754685	20040108
US 2004142028	A1	20040722	US 2004-754732	20040108
US 2004142031	A1	20040722	US 2004-754733	20040108

PRIORITY APPLN. INFO.:

EP 1997-201180	A	19970422
WO 1998-EP2361	W	19980420
US 1999-403139	A1	19991014
US 2002-117899	A1	20020408
US 2002-303494	B1	20021125

ED Entered STN: 09 Nov 1998

AB The invention pertains to a pharmaceutical dosage unit, such as a tablet or a capsule, comprising an effective amount of **tibolone** (0.1-10 % by weight) and a **starch**-containing pharmaceutically acceptable carrier (also denoted as basic granules), wherein the carrier contains 10-100% by weight of the **starch**. Thus, a more stable **tibolone** formulation is obtained, allowing dry storage and lower doses of active ingredient. Thus, basic granules contained **tibolone** 0.3, HPC 1.95, **corn starch** 32.5, Mg stearate 0.325, and lactose to 65 mg.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1994:686615 CAPLUS

DOCUMENT NUMBER: 121:286615

TITLE: Pharmaceutical compositions containing pregnane derivatives for the treatment of tumors.

INVENTOR(S): Deckers, Godefridus Hermanus Johanna; Kloosterboer, Helenius Jan

PATENT ASSIGNEE(S): Akazo Nobel N.V., Neth.

SOURCE: Eur. Pat. Appl., 9 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 613687	A1	19940907	EP 1994-200523	19940302

EP 613687 B1 19990602
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
 CA 2116829 AA 19940906 CA 1994-2116829 19940302
 CA 2116829 C 20040914
 AU 9457542 A1 19940908 AU 1994-57542 19940302
 AU 671706 B2 19960905
 ZA 9401464 A 19940927 ZA 1994-1464 19940302
 AT 180669 E 19990615 AT 1994-200523 19940302
 ES 2134313 T3 19991001 ES 1994-200523 19940302
 NO 9400777 A 19940906 NO 1994-777 19940304
 JP 07002673 A2 19950106 JP 1994-34540 19940304
 JP 3391539 B2 20030331
 US 5512556 A 19960430 US 1994-358639 19941219
 PRIORITY APPLN. INFO.: EP 1993-200631 A 19930305
 US 1994-206994 B1 19940307

OTHER SOURCE(S): MARPAT 121:286615

ED Entered STN: 10 Dec 1994

AB Pharmaceutical compns. containing pregnane derivs. (Markush structure given) are useful for prevention or treatment of tumors. A twice daily dose of 1 mg/kg (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one (I) inhibited the tumor growth in rats up to .apprx.70%. A tablet contained I 2.5, **starch** 10, **ascorbyl palmitate** 0.2, Mg stearate 0.5, and lactose q.s. to 100 mg.

L9 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1991:214521 CAPLUS

DOCUMENT NUMBER: 114:214521

TITLE: Pharmaceutical composition containing the pure crystalline forms of (7 α , 17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one

INVENTOR(S): Sas, G. A. J. M. T.; Van Doornum, E. M.

PATENT ASSIGNEE(S): AKZO N. V., Neth.

SOURCE: Eur. Pat. Appl., 13 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 389035	A1	19900926	EP 1990-200574	19900312
EP 389035	B1	19931215		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE				
ZA 9001674	A	19901228	ZA 1990-1674	19900305
CA 2011452	C	19990525	CA 1990-2011452	19900305
AT 98490	E	19940115	AT 1990-200574	19900312
ES 2062292	T3	19941216	ES 1990-200574	19900312
JP 03047195	A2	19910228	JP 1990-63921	19900314
JP 3139709	B2	20010305		
JP 2001139473	A2	20010522	JP 2000-316716	19900314
US 5037817	A	19910806	US 1990-494089	19900315
AU 9051394	A1	19900920	AU 1990-51394	19900316
AU 625083	B2	19920702		
FI 94865	B	19950731	FI 1990-1328	19900316
FI 94865	C	19951110		
KR 183401	B1	19990501	KR 1990-3574	19900317

PRIORITY APPLN. INFO.:

NL 1989-673 A 19890318
 EP 1990-200574 A 19900312
 JP 1990-63921 A3 19900314

ED Entered STN: 31 May 1991

AB Pure monoclinic or triclinic (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one (I) are more suitable for pharmaceutical compns. than the polymorphous I. A solution of 1 kg I in 23 L acetone containing

6 mL pyridine, was poured, under N, in 25 L water, followed by cooling to 0-5°, to crystallize monoclinic I (crystalline structure and x-ray diffraction spectrum given). Tablets comprised monoclinic I 2.5, starch 10, ascorbyl palmitate 0.2, Mg stearate 0.5, and lactose to 100 mg/tablet. I forms are useful for treating menopausal disorders, for immunomodulation, and for treating osteoporosis (no data).

=> d his

(FILE 'HOME' ENTERED AT 12:12:09 ON 25 MAR 2005)

FILE 'REGISTRY' ENTERED AT 12:12:34 ON 25 MAR 2005

E TIBOLONE/CN

L1 2 S E2-E3

FILE 'CAPLUS' ENTERED AT 12:12:50 ON 25 MAR 2005

L2 386 S L1

E TIBOLONE/BI

L3 359 S E2-E4

E TIBOLONE/CT

L4 430 S L2 OR L3

L5 147787 S STARCH? OR (POTATO STARCH?) OR (CORN STARCH?) OR (AMYLOMAIZE

L6 348947 S STABILIZER? OR (STABILIZING (W) (AGENT? OR COMPONENT? OR COMP

L7 78296 S (ASCORBYL PALMITATE?) OR "6-O-PALMITOYLASCORBIC ACID" OR "ASC

L8 61648 S LACTOSE OR DISACCHARIDE?

L9 5 S L4 AND L5 AND (L6 OR L7)

=> s tibolone? and starch?

358 TIBOLONE?

147702 STARCH?

L10 3 TIBOLONE? AND STARCH?

=> s l10 not l9

L11 0 L10 NOT L9

=> s l4 and l8

L12 7 L4 AND L8

=> s l12 not l9

L13 2 L12 NOT L9

=> d l13 1-2 ibib ed abs

L13 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:182541 CAPLUS

DOCUMENT NUMBER: 140:229476

TITLE: Treatment of dyspareunia with topically administered nitroglycerin formulations

INVENTOR(S): Place, Virgil A.; Wilson, Leland F.; Doherty, Paul C.; Hanamoto, Mark S.; Spivack, Alfred P.; Gesundheit, Neil; Bennett, Sean R.; Doherty, Jane K.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 18 pp., Cont.-in-part of U.S. Ser. No. 905,458.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

US 2004044080	A1	20040304	US 2003-407858	20030404
US 5877216	A	19990302	US 1997-959064	19971028
US 6306841	B1	20011023	US 2000-539484	20000330
US 2001051656	A1	20011213	US 2001-905458	20010713
US 6593313	B2	20030715		

PRIORITY APPLN. INFO.:

US 1997-959057	B2	19971028
US 1997-959064	A2	19971028
US 1998-181316	B1	19981027
US 2000-539484	A1	20000330
US 2001-905458	A2	20010713

ED Entered STN: 05 Mar 2004

AB Methods and formulations for treating dyspareunia are provided. A pharmaceutical composition formulated so as to contain a therapeutically effective amount of nitroglycerin is administered to the vagina or vulvar area of the individual undergoing treatment. Preferred formulations are immediate release formulations in which at least 80% of the nitroglycerin in the formulation is released therefrom within 4 h following administration. The formulations may contain one or more addnl. active agents, e.g., agents that are also useful to treat dyspareunia and/or potentiate the action of nitroglycerin. Such addnl. agents include vasoactive agents such as prostaglandins, phosphodiesterase inhibitors, androgens such as testosterone, estrogens such as estradiol, and selective modulators of estrogen and androgen receptors. A kit for a patient to use in the self-administration of the formulation is also provided.

L13 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:856713 CAPLUS

DOCUMENT NUMBER: 136:178102

TITLE: A pilot study of hormone replacement therapy with **tibolone** in women with mastopathic breasts

AUTHOR(S): Egarter, Christian; Eppel, Wolfgang; Vogel, Sonja; Wolf, Georg

CORPORATE SOURCE: Department of Obstetrics and Gynecology, University of Vienna, Vienna, 1010, Austria

SOURCE: Maturitas (2001), 40(2), 165-171

CODEN: MATUDK; ISSN: 0378-5122

PUBLISHER: Elsevier Science Ireland Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 27 Nov 2001

AB The authors' purpose was to investigate the effect of **tibolone** in a prospective randomized, double-blind pilot study in postmenopausal women with clin. palpable mastopathic changes. Twenty postmenopausal non-users of hormone replacement therapy undergoing mammog. were randomly allocated to receive either 2.5 mg **tibolone** (Livial, Organon) or placebo (2 mg **lactose**). Mammog. d. according to the Wolfe classification, severity of breast discomfort, parity, smoking habits, body weight and FSH and estradiol (E2) levels were documented at baseline and after 6 mo of treatment. There were no statistically significant differences between the two treatment groups in terms of parity, smoking, body weight and FSH and E2 levels. At 6 mo, four patients in the **tibolone** group showed reduced breast d., compared with one patient in the placebo group. Whereas no significant differences were found between the two treatment groups when the categories 'minimal reduction' and 'reduction' in mammog. d. were combined, combination of the categories 'no change' and 'minimal reduction' showed a significant difference. Also, women in the **tibolone** group showed a statistically significant improvement in breast discomfort. This pilot study showed decreases in breast d. as well as an attendant significant alleviation of breast discomfort in women with baseline mastopathic changes treated with **tibolone** for 6 mo, which may be due to the inhibitory effect of **tibolone** on the enzymes involved in the biosynthesis of estradiol demonstrated in previous trials and should be further evaluated in long-term studies.

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 12:12:09 ON 25 MAR 2005)

FILE 'REGISTRY' ENTERED AT 12:12:34 ON 25 MAR 2005

E TIBOLONE/CN

L1 2 S E2-E3

FILE 'CAPLUS' ENTERED AT 12:12:50 ON 25 MAR 2005

L2 386 S L1

E TIBOLONE/BI

L3 359 S E2-E4

E TIBOLONE/CT

L4 430 S L2 OR L3

L5 147787 S STARCH? OR (POTATO STARCH?) OR (CORN STARCH?) OR (AMYLOMAIZE

L6 348947 S STABILIZER? OR (STABILIZING (W) (AGENT? OR COMPONENT? OR COMP

L7 78296 S (ASCORBYL PALMITATE?) OR "6-O-PALMITOYLASCORBIC ACID" OR "ASC

L8 61648 S LACTOSE OR DISACCHARIDE?

L9 5 S L4 AND L5 AND (L6 OR L7)

L10 3 S TIBOLONE? AND STARCH?

L11 0 S L10 NOT L9

L12 7 S L4 AND L8

L13 2 S L12 NOT L9

=> d cost

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
CONNECT CHARGES	6.63
6.63	7.15
NETWORK CHARGES	1.02
1.02	1.14
SEARCH CHARGES	107.73
107.73	116.93
DISPLAY CHARGES	18.55
18.55	18.55
-----	-----
FULL ESTIMATED COST	133.93
133.93	143.77

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
CA SUBSCRIBER PRICE	-5.11
-5.11	-5.11

IN FILE 'CAPLUS' AT 12:23:14 ON 25 MAR 2005

=> e haan p/au

E1 14 HAAN O/AU
E2 3 HAAN OSWALD/AU
E3 1 --> HAAN P/AU
E4 1 HAAN P K/AU
E5 1 HAAN P V D/AU
E6 1 HAAN PATRICIA KAY/AU
E7 1 HAAN PIETER/AU
E8 1 HAAN POUL DE/AU
E9 3 HAAN R E/AU
E10 1 HAAN RENE JOHAN/AU
E11 1 HAAN ROBERT EDGAR/AU
E12 17 HAAN S/AU

=> s e3,e5,e7

1 "HAAN P"/AU

1 "HAAN P V D"/AU

1 "HAAN PIETER"/AU

L14 3 ("HAAN P"/AU OR "HAAN P V D"/AU OR "HAAN PIETER"/AU)

=> e de haan p/au

E1	4	DE HAAN N/AU
E2	9	DE HAAN N A/AU
E3	46 -->	DE HAAN P/AU
E4	1	DE HAAN P A J/AU
E5	1	DE HAAN P C M/AU
E6	1	DE HAAN P E/AU
E7	13	DE HAAN P G/AU
E8	16	DE HAAN P H/AU
E9	2	DE HAAN P T/AU
E10	1	DE HAAN PATRICIA F/AU
E11	1	DE HAAN PAUL E/AU
E12	45	DE HAAN PETER/AU

=> e

E13	1	DE HAAN PETER G/AU
E14	2	DE HAAN PETER HILLEBRAND/AU
E15	1	DE HAAN PETRUS T/AU
E16	10	DE HAAN PETRUS THEODORUS/AU
E17	1	DE HAAN PIET/AU
E18	15	DE HAAN PIETER/AU
E19	2	DE HAAN POUL/AU
E20	1	DE HAAN Q C/AU
E21	6	DE HAAN R/AU
E22	1	DE HAAN R A/AU
E23	10	DE HAAN R C/AU
E24	1	DE HAAN R F/AU

=> s e3-e9, e17-e18

	46	"DE HAAN P"/AU
	1	"DE HAAN P A J"/AU
	1	"DE HAAN P C M"/AU
	1	"DE HAAN P E"/AU
	13	"DE HAAN P G"/AU
	16	"DE HAAN P H"/AU
	2	"DE HAAN P T"/AU
	1	"DE HAAN PIET"/AU
	15	"DE HAAN PIETER"/AU
L15	96	("DE HAAN P"/AU OR "DE HAAN P A J"/AU OR "DE HAAN P C M"/AU OR "DE HAAN P E"/AU OR "DE HAAN P G"/AU OR "DE HAAN P H"/AU OR "DE HAAN P T"/AU OR "DE HAAN PIET"/AU OR "DE HAAN PIETER"/AU)

=> e lambregts t/au

E1	1	LAMBREGTS P C L A/AU
E2	1	LAMBREGTS R M/AU
E3	0 -->	LAMBREGTS T/AU
E4	1	LAMBREGTS VAN DEN HURK THEODORA ANTONIA MARIA/AU
E5	1	LAMBREGTS W A/AU
E6	9	LAMBREMONT E N/AU
E7	36	LAMBREMONT EDWARD N/AU
E8	9	LAMBREMONT YVES/AU
E9	1	LAMBRERA MAYA/AU
E10	1	LAMBRERETH J L/AU
E11	1	LAMBRET B/AU
E12	5	LAMBRET BERNARD/AU

=> s e4

L16	1	"LAMBREGTS VAN DEN HURK THEODORA ANTONIA MARIA"/AU
-----	---	--

=> e hurk t/au

E1	1	HURK MARTIN K/AU
E2	1	HURK S VAN DRUNEN LITTLE VAN DEN/AU
E3	0 -->	HURK T/AU

E4	2	HURKA DR G/AU
E5	3	HURKA G/AU
E6	1	HURKA GERTRAUD/AU
E7	13	HURKA H/AU
E8	13	HURKA HERBERT/AU
E9	1	HURKA JAROSLAV/AU
E10	2	HURKA JOSEF/AU
E11	1	HURKA R/AU
E12	2	HURKA RUDOLPH J/AU

=> e vd hurk t/au

E1	1	VD BOOMGAARD T/AU
E2	1	VD HEYDEN J J/AU
E3	0 -->	VD HURK T/AU
E4	1	VD LAAK WILLEM JANSSEN/AU
E5	1	VD LELY A J/AU
E6	1	VD LINDEN G H M/AU
E7	1	VD STEEG L M A/AU
E8	1	VD VELDE E A/AU
E9	1	VD WATT MARYLYN/AU
E10	1	VDACHIN B G/AU
E11	1	VDALEEV R G/AU
E12	1	VDEH B F I/AU

=> e van den hurk t/au

E1	1	VAN DEN HURK RONALD ARIE/AU
E2	3	VAN DEN HURK SYLVIA/AU
E3	0 -->	VAN DEN HURK T/AU
E4	1	VAN DEN HURK TH A M/AU
E5	1	VAN DEN HURK W H/AU
E6	1	VAN DEN HURK WILHELMINA/AU
E7	6	VAN DEN HURK WILHELMINA H/AU
E8	1	VAN DEN IDSERT P/AU
E9	1	VAN DEN IJSSEL J/AU
E10	2	VAN DEN IJSSEL JAN/AU
E11	2	VAN DEN IJSSEL P R L A/AU
E12	8	VAN DEN IJSSEL PAUL/AU

=> s e4

L17	1	"VAN DEN HURK TH A M"/AU
-----	---	--------------------------

=> e morita r/au

E1	4	MORITA OSAYUKI/AU
E2	1	MORITA OUKI/AU
E3	53 -->	MORITA R/AU
E4	3	MORITA R S/AU
E5	3	MORITA R SAITO/AU
E6	24	MORITA R Y/AU
E7	2	MORITA REIJI/AU
E8	31	MORITA REIKO/AU
E9	1	MORITA REIKO SAITO/AU
E10	1	MORITA RICHARD U/AU
E11	74	MORITA RICHARD Y/AU
E12	1	MORITA RICHARDY Y/AU

=> e

E13	4	MORITA RIE/AU
E14	4	MORITA RIICHIRO/AU
E15	6	MORITA RIKA/AU
E16	1	MORITA RIKAKO/AU
E17	2	MORITA RIKUJI/AU
E18	101	MORITA RIKUSHI/AU
E19	2	MORITA RIMPEI/AU
E20	1	MORITA RINITSU/AU

E21 2 MORITA RINPEI/AU
 E22 1 MORITA RITSUO/AU
 E23 14 MORITA RYOICHI/AU
 E24 65 MORITA RYOJI/AU

=> s e3-e6, e23

53 "MORITA R"/AU
 3 "MORITA R S"/AU
 3 "MORITA R SAITO"/AU
 24 "MORITA R Y"/AU
 14 "MORITA RYOICHI"/AU
 L18 97 ("MORITA R"/AU OR "MORITA R S"/AU OR "MORITA R SAITO"/AU OR
 "MORITA R Y"/AU OR "MORITA RYOICHI"/AU)

=> e rovers a/au

E1 2 ROVERONI G/AU
 E2 3 ROVERONI GIOVANNI/AU
 E3 0 --> ROVERS A/AU
 E4 1 ROVERS ADRIANUS CORNELIS PETRUS/AU
 E5 2 ROVERS CHANTAL/AU
 E6 1 ROVERS ERIC/AU
 E7 2 ROVERS F/AU
 E8 7 ROVERS F A/AU
 E9 19 ROVERS FRANK/AU
 E10 18 ROVERS FRANK A/AU
 E11 1 ROVERS GERBEN/AU
 E12 1 ROVERS GERBEN M L L/AU

=> s e4

L19 1 "ROVERS ADRIANUS CORNELIS PETRUS"/AU

=> e zwinkels j/au

E1 1 ZWINGMANN WERNER/AU
 E2 1 ZWINK WALTER/AU
 E3 1 --> ZWINKELS J/AU
 E4 8 ZWINKELS J C/AU
 E5 1 ZWINKELS J C M/AU
 E6 11 ZWINKELS JOANNE C/AU
 E7 2 ZWINKELS JOANNE C M/AU
 E8 2 ZWINKELS JOCOMINUS ANTONIUS MARIA/AU
 E9 1 ZWINKELS M/AU
 E10 6 ZWINKELS M F M/AU
 E11 1 ZWINKELS M G J/AU
 E12 9 ZWINKELS MARCO/AU

=> s e3, e8

1 "ZWINKELS J"/AU
 2 "ZWINKELS JOCOMINUS ANTONIUS MARIA"/AU
 L20 3 ("ZWINKELS J"/AU OR "ZWINKELS JOCOMINUS ANTONIUS MARIA"/AU)

=> d his

(FILE 'HOME' ENTERED AT 12:12:09 ON 25 MAR 2005)

FILE 'REGISTRY' ENTERED AT 12:12:34 ON 25 MAR 2005

E TIBOLONE/CN
 L1 2 S E2-E3

FILE 'CAPLUS' ENTERED AT 12:12:50 ON 25 MAR 2005

L2 386 S L1
 E TIBOLONE/BI
 L3 359 S E2-E4
 E TIBOLONE/CT
 L4 430 S L2 OR L3

L5 147787 S STARCH? OR (POTATO STARCH?) OR (CORN STARCH?) OR (AMYLOMAIZE
 L6 348947 S STABILIZER? OR (STABILIZING (W) (AGENT? OR COMPONENT? OR COMP
 L7 78296 S (ASCORBYL PALMITATE?) OR "6-O-PALMITOYLASCORBIC ACID" OR "ASC
 L8 61648 S LACTOSE OR DISACCHARIDE?
 L9 5 S L4 AND L5 AND (L6 OR L7)
 L10 3 S TIBOLONE? AND STARCH?
 L11 0 S L10 NOT L9
 L12 7 S L4 AND L8
 L13 2 S L12 NOT L9
 E HAAN P/AU
 L14 3 S E3,E5,E7
 E DE HAAN P/AU
 L15 96 S E3-E9, E17-E18
 E LAMBREGTS T/AU
 L16 1 S E4
 E HURK T/AU
 E VD HURK T/AU
 E VAN DEN HURK T/AU
 L17 1 S E4
 E MORITA R/AU
 L18 97 S E3-E6, E23
 E ROVERS A/AU
 L19 1 S E4
 E ZWINKELS J/AU
 L20 3 S E3, E8

=> s l14 or l15

L21 99 L14 OR L15

=> s l21 or l16 or l17 or l18 or l19 or l20

L22 198 L21 OR L16 OR L17 OR L18 OR L19 OR L20

=> s l22 and tibolone?

358 TIBOLONE?

L23 4 L22 AND TIBOLONE?

=> d l23 1-4 ibib ed abs

L23 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:1036906 CAPLUS

DOCUMENT NUMBER: 142:11606

TITLE: Immediate-release pharmaceutical dosage form
comprising a **tibolone** polymorph

INVENTOR(S): **De Haan, Pieter**

PATENT ASSIGNEE(S): Akzo Nobel N.V., Neth.

SOURCE: PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004103378	A1	20041202	WO 2004-EP50852	20040519
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,			

SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG
 CA 2473718 AA 20041123 CA 2004-2473718 20040519
 EP 1499278 A1 20050126 EP 2004-737220 20040519
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
 PRIORITY APPLN. INFO.: EP 2003-101500 A 20030523
 WO 2004-EP50852 W 20040519

ED Entered STN: 03 Dec 2004

AB An immediate-release pharmaceutical dosage form comprises a
tibolone polymorph and excipients, wherein the polymorph has a
 mean particle size as defined in the specification of below 22.8 µm in
 the dosage form. Thus, an immediate-release tablet formulation contained
tibolone 2.5, potato starch 10, ascorbyl palmitate 0.2, Mg
 stearate 0.5, and lactose 86.8 mg.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:999673 CAPLUS

DOCUMENT NUMBER: 141:415963

TITLE: Immediate release dosage form for hormone replacement
 therapy

INVENTOR(S): De Haan, Pieter

PATENT ASSIGNEE(S): Neth.

SOURCE: U.S. Pat. Appl. Publ., 10 pp., Division of U.S. Ser.
 No. 723,412, abandoned.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004229854	A1	20041118	US 2004-781493	20040218
PRIORITY APPLN. INFO.:			US 2000-723412	B3 20001128

ED Entered STN: 19 Nov 2004

AB It has been recognized that **tibolone**, which is an agent in the
 treatment of menopausal complaints and osteoporosis, if formulated with a
 particle size in a defined range, displays an unexpectedly high
 bioavailability of one of its estrogenic metabolites, Org A.

L23 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:453011 CAPLUS

DOCUMENT NUMBER: 140:429053

TITLE: Pharmaceutical tablets containing **tibolone**
 and a coating

INVENTOR(S): De Haan, Pieter; Van Lare, Cornelis
 Elisabeth Johannus

PATENT ASSIGNEE(S): Akzo Nobel N.V., Neth.

SOURCE: PCT Int. Appl., 20 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004045587	A1	20040603	WO 2003-EP50829	20031113
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,			

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
 NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: EP 2002-79920 A 20021120
 US 2002-427740P P 20021120

ED Entered STN: 04 Jun 2004

AB The present invention relates to a stabilized pharmaceutical tablet comprising an amount of from 0.1 to 10% by weight of **tibolone** provided with a coating, such as a film coating, a sugar coating, a sugar film coating or a wrap coating. The invention further relates to the use of a coating for stabilizing a pharmaceutical tablet comprising **tibolone**. Preferably, the coating is a sugar coating or a sugar film coating. Preferably, the sugar comprises sucrose. These tablets were shown to have a lower amount of OM38, i.e. an isomerization degradation product of **tibolone**, after storage as compared to uncoated **tibolone** tablets. For example, a tablet was formulated containing **tibolone**, basic granulates (starch/lactose), ascorbyl palmitate, and Mg stearate and a film-coated with a composition containing hydroxypropyl

Me cellulose, polyethylene glycol, titania, and talc, further coated with a composition containing arabic gum, saccharose, Ca carbonate, talc, titania, polyethylene glycol, glucose syrup, glycerol, and china clay.

L23 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:708947 CAPLUS
 DOCUMENT NUMBER: 129:335779
 TITLE: Stabilized **tibolone** compositions
 INVENTOR(S): Haan De, Pieter; **Rovers, Adrianus Cornelis Petrus**; Lambregts-De Hurk, Theodora Antonia Maria; **Zwinkels, Jocominus Antonius Maria; Morita, Ryoichi**
 PATENT ASSIGNEE(S): Akzo Nobel N.V., Neth.
 SOURCE: PCT Int. Appl., 21 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9847517	A1	19981029	WO 1998-EP2361	19980420
W: AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, ID, IS, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
IL 123984	A1	20040927	IL 1998-123984	19980407
ZA 9803169	A	19981020	ZA 1998-3169	19980415
CA 2288070	AA	19981029	CA 1998-2288070	19980420
AU 9880146	A1	19981113	AU 1998-80146	19980420
AU 742037	B2	20011213		
EP 975348	A1	20000202	EP 1998-928214	19980420
EP 975348	B1	20041110		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
TR 9902530	T2	20000522	TR 1999-9902530	19980420
BR 9809268	A	20000627	BR 1998-9268	19980420

NZ 338028	A	20011026	NZ 1998-338028	19980420
RU 2207133	C2	20030627	RU 1999-121407	19980420
AT 281836	E	20041115	AT 1998-928214	19980420
JP 10316573	A2	19981202	JP 1998-112312	19980422
TW 570798	B	20040111	TW 1998-87107211	19980511
US 2001005513	A1	20010628	US 1999-403139	19991014
US 6399594	B2	20020604		
NO 9905127	A	19991021	NO 1999-5127	19991021
MX 9909676	A	20000331	MX 1999-9676	19991021
US 6514958	B1	20030204	US 2002-117899	20020408
US 2003119801	A1	20030626	US 2002-303494	20021125
US 2004142030	A1	20040722	US 2004-754685	20040108
US 2004142028	A1	20040722	US 2004-754732	20040108
US 2004142031	A1	20040722	US 2004-754733	20040108
PRIORITY APPLN. INFO.:			EP 1997-201180	A 19970422
			WO 1998-EP2361	W 19980420
			US 1999-403139	A1 19991014
			US 2002-117899	A1 20020408
			US 2002-303494	B1 20021125

ED Entered STN: 09 Nov 1998

AB The invention pertains to a pharmaceutical dosage unit, such as a tablet or a capsule, comprising an effective amount of **tibolone** (0.1-10 % by weight) and a starch-containing pharmaceutically acceptable carrier (also denoted as basic granules), wherein the carrier contains 10-100% by weight of the starch. Thus, a more stable **tibolone** formulation is obtained, allowing dry storage and lower doses of active ingredient. Thus, basic granules contained **tibolone** 0.3, HPC 1.95, corn starch 32.5, Mg stearate 0.325, and lactose to 65 mg.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 12:12:09 ON 25 MAR 2005)

FILE 'REGISTRY' ENTERED AT 12:12:34 ON 25 MAR 2005

E TIBOLONE/CN

L1 2 S E2-E3

FILE 'CAPLUS' ENTERED AT 12:12:50 ON 25 MAR 2005

L2 386 S L1

E TIBOLONE/BI

L3 359 S E2-E4

E TIBOLONE/CT

L4 430 S L2 OR L3

L5 147787 S STARCH? OR (POTATO STARCH?) OR (CORN STARCH?) OR (AMYLOMAIZE

L6 348947 S STABILIZER? OR (STABILIZING (W) (AGENT? OR COMPONENT? OR COMP

L7 78296 S (ASCORBYL PALMITATE?) OR "6-O-PALMITOYLASCORBIC ACID" OR "ASC

L8 61648 S LACTOSE OR DISACCHARIDE?

L9 5 S L4 AND L5 AND (L6 OR L7)

L10 3 S TIBOLONE? AND STARCH?

L11 0 S L10 NOT L9

L12 7 S L4 AND L8

L13 2 S L12 NOT L9

E HAAN P/AU

L14 3 S E3,E5,E7

E DE HAAN P/AU

L15 96 S E3-E9, E17-E18

E LAMBREGTS T/AU

L16 1 S E4

E HURK T/AU

E VD HURK T/AU

E VAN DEN HURK T/AU

L17 1 S E4
 E MORITA R/AU
 L18 97 S E3-E6, E23
 E ROVERS A/AU
 L19 1 S E4
 E ZWINKELS J/AU
 L20 3 S E3, E8
 L21 99 S L14 OR L15
 L22 198 S L21 OR L16 OR L17 OR L18 OR L19 OR L20
 L23 4 S L22 AND TIBOLONE?

=> d cost

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
CONNECT CHARGES	10.53	11.05
NETWORK CHARGES	1.62	1.74
SEARCH CHARGES	151.20	160.40
DISPLAY CHARGES	29.15	29.15
	-----	-----
FULL ESTIMATED COST	192.50	202.34
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-8.03	-8.03

IN FILE 'CAPLUS' AT 12:29:14 ON 25 MAR 2005

=> file medline biosis caplus embase wpids

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	192.95	202.79
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-8.03	-8.03

FILE 'MEDLINE' ENTERED AT 12:29:23 ON 25 MAR 2005

FILE 'BIOSIS' ENTERED AT 12:29:23 ON 25 MAR 2005

Copyright (c) 2005 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 12:29:23 ON 25 MAR 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 12:29:23 ON 25 MAR 2005

COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 12:29:23 ON 25 MAR 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

=> s tibolone? or livial? or liviella? or boltin? or "Org OD14"

L24 8818 TIBOLONE? OR LIVIAL? OR LIVIELLA? OR BOLTIN? OR "ORG OD14"

=> s l24 not boltin?

L25 2399 L24 NOT BOLTIN?

=> s tibolone? or livial? or liviella? or "ORG OD14" or "Org OD14" or "Org-OD14" or "ORG-OD14"

L26 2401 TIBOLONE? OR LIVIAL? OR LIVIELLA? OR "ORG OD14" OR "ORG OD14" OR "ORG-OD14" OR "ORG-OD14"

=> s starch? or (potato starch?) or (corn starch?) or (amylomaize starch?) or amylum? or keoflo? or (wheat starch?) or (modified starch?) or (agglomerated starch?) or (granulated starch?)

L27 276310 STARCH? OR (POTATO STARCH?) OR (CORN STARCH?) OR (AMYLOMAIZE STARCH?) OR AMYLUM? OR KEOFLO? OR (WHEAT STARCH?) OR (MODIFIED STARCH?) OR (AGGLOMERATED STARCH?) OR (GRANULATED STARCH?)

=> s stabilizer? or (stabilizing (W) (agent? or component? or compound?)) or (antioxida?) or (chelate?)

4 FILES SEARCHED...

L28 693483 STABILIZER? OR (STABILIZING (W) (AGENT? OR COMPONENT? OR COMPOUND?)) OR (ANTIOXIDA?) OR (CHELATE?)

=> s (ascorbyl palmitate?) or "6-O-palmitoylascorbic acid" or "ascorbate-6-palmitate" or "vitamin C palmitate" or "ascorbic-6-O-palmitate" or (ascorbyl stearate?) or (sodium ascorbate?) or (ascorbic acid?) or hybrin? or "L-ascorbic acid"

2 FILES SEARCHED...

L29 176163 (ASCORBYL PALMITATE?) OR "6-O-PALMITOYLASCORBIC ACID" OR "ASCORBATE-6-PALMITATE" OR "VITAMIN C PALMITATE" OR "ASCORBIC-6-O-PALMITATE" OR (ASCORBYL STEARATE?) OR (SODIUM ASCORBATE?) OR (ASCORBIC ACID?) OR HYBRIN? OR "L-ASCORBIC ACID"

=> s lactose or disaccharide?

L30 139122 LACTOSE OR DISACCHARIDE?

=> d his

(FILE 'HOME' ENTERED AT 12:12:09 ON 25 MAR 2005)

FILE 'REGISTRY' ENTERED AT 12:12:34 ON 25 MAR 2005

E TIBOLONE/CN

L1 2 S E2-E3

FILE 'CAPLUS' ENTERED AT 12:12:50 ON 25 MAR 2005

L2 386 S L1

E TIBOLONE/BI

L3 359 S E2-E4

E TIBOLONE/CT

L4 430 S L2 OR L3

L5 147787 S STARCH? OR (POTATO STARCH?) OR (CORN STARCH?) OR (AMYLOMAIZE

L6 348947 S STABILIZER? OR (STABILIZING (W) (AGENT? OR COMPONENT? OR COMP

L7 78296 S (ASCORBYL PALMITATE?) OR "6-O-PALMITOYLASCORBIC ACID" OR "ASC

L8 61648 S LACTOSE OR DISACCHARIDE?

L9 5 S L4 AND L5 AND (L6 OR L7)

L10 3 S TIBOLONE? AND STARCH?

L11 0 S L10 NOT L9

L12 7 S L4 AND L8

L13 2 S L12 NOT L9

E HAAN P/AU

L14 3 S E3,E5,E7

E DE HAAN P/AU

L15 96 S E3-E9, E17-E18

E LAMBREGTS T/AU

L16 1 S E4

E HURK T/AU

E VD HURK T/AU

E VAN DEN HURK T/AU

L17 1 S E4

E MORITA R/AU

L18 97 S E3-E6, E23

E ROVERS A/AU

L19 1 S E4

E ZWINKELS J/AU

L20 3 S E3, E8
 L21 99 S L14 OR L15
 L22 198 S L21 OR L16 OR L17 OR L18 OR L19 OR L20
 L23 4 S L22 AND TIBOLONE?

FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE, WPIDS' ENTERED AT 12:29:23 ON 25
 MAR 2005

L24 8818 S TIBOLONE? OR LIVIAL? OR LIVIELLA? OR BOLTIN? OR "ORG OD14"
 L25 2399 S L24 NOT BOLTIN?
 L26 2401 S TIBOLONE? OR LIVIAL? OR LIVIELLA? OR "ORG OD14" OR "ORG OD14"
 L27 276310 S STARCH? OR (POTATO STARCH?) OR (CORN STARCH?) OR (AMYLOMAIZE
 L28 693483 S STABILIZER? OR (STABILIZING (W) (AGENT? OR COMPONENT? OR COMP
 L29 176163 S (ASCORBYL PALMITATE?) OR "6-O-PALMITOYLASCORBIC ACID" OR "ASC
 L30 139122 S LACTOSE OR DISACCHARIDE?

=> s 126 and 127 and (128 or 129)
 L31 3 L26 AND L27 AND (L28 OR L29)

=> dup rem l31
 PROCESSING COMPLETED FOR L31
 L32 3 DUP REM L31 (0 DUPLICATES REMOVED)
 ANSWERS '1-3' FROM FILE CAPLUS

=> d l32 1-3 ibib ed abs

L32 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:1036906 CAPLUS
 DOCUMENT NUMBER: 142:11606
 TITLE: Immediate-release pharmaceutical dosage form
 comprising a **tibolone** polymorph
 INVENTOR(S): De Haan, Pieter
 PATENT ASSIGNEE(S): Akzo Nobel N.V., Neth.
 SOURCE: PCT Int. Appl., 32 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004103378	A1	20041202	WO 2004-EP50852	20040519
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2473718	AA	20041123	CA 2004-2473718	20040519
EP 1499278	A1	20050126	EP 2004-737220	20040519
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRIORITY APPLN. INFO.:			EP 2003-101500	A 20030523
			WO 2004-EP50852	W 20040519

ED Entered STN: 03 Dec 2004

AB An immediate-release pharmaceutical dosage form comprises a
tibolone polymorph and excipients, wherein the polymorph has a
 mean particle size as defined in the specification of below 22.8 µm in
 the dosage form. Thus, an immediate-release tablet formulation contained

tibolone 2.5, **potato starch** 10,
ascorbyl palmitate 0.2, Mg stearate 0.5, and lactose
86.8 mg.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:453011 CAPLUS

DOCUMENT NUMBER: 140:429053

TITLE: Pharmaceutical tablets containing **tibolone**
and a coating

INVENTOR(S): De Haan, Pieter; Van Lare, Cornelis Elisabeth Johannus

PATENT ASSIGNEE(S): Akzo Nobel N.V., Neth.

SOURCE: PCT Int. Appl., 20 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004045587	A1	20040603	WO 2003-EP50829	20031113
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			EP 2002-79920 US 2002-427740P	A 20021120 P 20021120

ED Entered STN: 04 Jun 2004

AB The present invention relates to a stabilized pharmaceutical tablet comprising an amount of from 0.1 to 10% by weight of **tibolone** provided with a coating, such as a film coating, a sugar coating, a sugar film coating or a wrap coating. The invention further relates to the use of a coating for stabilizing a pharmaceutical tablet comprising **tibolone**. Preferably, the coating is a sugar coating or a sugar film coating. Preferably, the sugar comprises sucrose. These tablets were shown to have a lower amount of OM38, i.e. an isomerization degradation product of **tibolone**, after storage as compared to uncoated **tibolone** tablets. For example, a tablet was formulated containing **tibolone**, basic granulates (**starch**/lactose), **ascorbyl palmitate**, and Mg stearate and a film-coated with a composition containing hydroxypropyl Me cellulose, polyethylene glycol, titania, and talc, further coated with a composition containing arabic gum, saccharose, Ca carbonate, talc, titania, polyethylene glycol, glucose syrup, glycerol, and china clay.

L32 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:708947 CAPLUS

DOCUMENT NUMBER: 129:335779

TITLE: Stabilized **tibolone** compositions

INVENTOR(S): Haan De, Pieter; Rovers, Adrianus Cornelis Petrus;
Lambregts-De Hurk, Theodora Antonia Maria; Zwinkels,
Jocominus Antonius Maria; Morita, Ryoichi

PATENT ASSIGNEE(S): Akzo Nobel N.V., Neth.

SOURCE: PCT Int. Appl., 21 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9847517	A1	19981029	WO 1998-EP2361	19980420
W: AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, ID, IS, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
IL 123984	A1	20040927	IL 1998-123984	19980407
ZA 9803169	A	19981020	ZA 1998-3169	19980415
CA 2288070	AA	19981029	CA 1998-2288070	19980420
AU 9880146	A1	19981113	AU 1998-80146	19980420
AU 742037	B2	20011213		
EP 975348	A1	20000202	EP 1998-928214	19980420
EP 975348	B1	20041110		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
TR 9902530	T2	20000522	TR 1999-9902530	19980420
BR 9809268	A	20000627	BR 1998-9268	19980420
NZ 338028	A	20011026	NZ 1998-338028	19980420
RU 2207133	C2	20030627	RU 1999-121407	19980420
AT 281836	E	20041115	AT 1998-928214	19980420
JP 10316573	A2	19981202	JP 1998-112312	19980422
TW 570798	B	20040111	TW 1998-87107211	19980511
US 2001005513	A1	20010628	US 1999-403139	19991014
US 6399594	B2	20020604		
NO 9905127	A	19991021	NO 1999-5127	19991021
MX 9909676	A	20000331	MX 1999-9676	19991021
US 6514958	B1	20030204	US 2002-117899	20020408
US 2003119801	A1	20030626	US 2002-303494	20021125
US 2004142030	A1	20040722	US 2004-754685	20040108
US 2004142028	A1	20040722	US 2004-754732	20040108
US 2004142031	A1	20040722	US 2004-754733	20040108
PRIORITY APPLN. INFO.:			EP 1997-201180	A 19970422
			WO 1998-EP2361	W 19980420
			US 1999-403139	A1 19991014
			US 2002-117899	A1 20020408
			US 2002-303494	B1 20021125
ED	Entered STN: 09 Nov 1998			
AB	The invention pertains to a pharmaceutical dosage unit, such as a tablet or a capsule, comprising an effective amount of tibolone (0.1-10 % by weight) and a starch -containing pharmaceutically acceptable carrier (also denoted as basic granules), wherein the carrier contains 10-100% by weight of the starch . Thus, a more stable tibolone formulation is obtained, allowing dry storage and lower doses of active ingredient. Thus, basic granules contained tibolone 0.3, HPC 1.95, corn starch 32.5, Mg stearate 0.325, and lactose to 65 mg.			
REFERENCE COUNT:	5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		
=> s tibolone? and starch?				
L33	6 TIBOLONE? AND STARCH?			
=> dup rem l33				
PROCESSING COMPLETED FOR L33				
L34	5 DUP REM L33 (1 DUPLICATE REMOVED)			

ANSWER '1' FROM FILE BIOSIS
ANSWERS '2-4' FROM FILE CAPLUS
ANSWER '5' FROM FILE WPIDS

=> s 134 not 132
L35 2 L34 NOT L32

=> d 135 1-2 ibib ed abs

L35 ANSWER 1 OF 2 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 2002:378050 BIOSIS
DOCUMENT NUMBER: PREV200200378050
TITLE: Stabilized **tibolone** compositions.
AUTHOR(S): de Haan, Pieter [Inventor, Reprint author]; Lambregts v.d.
Hurk, Theodora Antonia Maria [Inventor]; Morita, Ryoichi
[Inventor]; Rovers, Adrianus Cornelis Petrus [Inventor];
Zwinkels, Jocominus Antonius Maria [Inventor]
CORPORATE SOURCE: Oss, Netherlands
ASSIGNEE: Akzo Nobel NV, Arnhem, Netherlands
PATENT INFORMATION: US 6399594 June 04, 2002
SOURCE: Official Gazette of the United States Patent and Trademark
Office Patents, (June 4, 2002) Vol. 1259, No. 1.
<http://www.uspto.gov/web/menu/patdata.html>. e-file.
CODEN: OGUPE7. ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English
ENTRY DATE: Entered STN: 10 Jul 2002
Last Updated on STN: 10 Jul 2002

ED Entered STN: 10 Jul 2002

Last Updated on STN: 10 Jul 2002

AB The invention pertains to a pharmaceutical dosage unit, such as a tablet
or a capsule, comprising an effective amount of **tibolone**
(generally of from 0.1 to 10% by weight) and a **starch**-containing
pharmaceutically acceptable carrier (also denoted as basic granulate),
wherein the carrier contains of from 10 to 100% by weight of the
starch. Thus a more stable **tibolone** formulation is
obtained, allowing dry storage and lower doses of active ingredient.

L35 ANSWER 2 OF 2 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 2003-393472 [37] WPIDS
DOC. NO. CPI: C2003-104580
TITLE: **Tibolone** formulations with improved stability,
useful as a gonadomimetic and immunomodulator, and for
inhibiting ovulation.
DERWENT CLASS: A96 B01
INVENTOR(S): BRENNAN, T; WOOLFE, A J
PATENT ASSIGNEE(S): (BREN-I) BRENNAN T; (WOOL-I) WOOLFE A J; (IVAX-N) IVAX
CORP; (NORT-N) NORTON HEALTHCARE LTD
COUNTRY COUNT: 101
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2003032924	A2	20030424	(200337)*	EN	19
RW:	AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR IE IT KE LS LU				
	MC MW MZ NL OA PT SD SE SK SL SZ TR TZ UG ZM ZW				
W:	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK				
	DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR				
	KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT				
	RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW				
US 2003134832	A1	20030717	(200348)		
EP 1444247	A2	20040811	(200452)	EN	
R:	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LT LU LV MC				
	MK NL PT RO SE SI SK TR				

AU 2002347973 A1 20030428 (200460)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2003032924	A2	WO 2002-US33526	20021018
US 2003134832	A1 Provisional	US 2001-350121P	20011102
		US 2002-273455	20021018
EP 1444247	A2	EP 2002-784184	20021018
		WO 2002-US33526	20021018
AU 2002347973	A1	AU 2002-347973	20021018

FILING DETAILS:

PATENT NO	KIND	PATENT NO
EP 1444247	A2 Based on	WO 2003032924
AU 2002347973	A1 Based on	WO 2003032924

PRIORITY APPLN. INFO: US 2001-350121P 20011102; GB
2001-25061 20011018

ED 20030612

AN 2003-393472 [37] WPIDS

AB WO2003032924 A UPAB: 20030612

NOVELTY - A composition comprises **tibolone**, one or more
excipients, and a pH adjusting agent.

ACTIVITY - Immunomodulator; Gynecological.

MECHANISM OF ACTION - Gonadomimetic.

USE - **Tibolone** has gonadomimetic, ovulation-inhibiting and
immuno-modulatory action.

ADVANTAGE - The inclusion of a pH adjusting agent improves the
stability of the compositions, even those with a low **tibolone**
content, and retains their solubility.

Dwg.0/2

=> d his

(FILE 'HOME' ENTERED AT 12:12:09 ON 25 MAR 2005)

FILE 'REGISTRY' ENTERED AT 12:12:34 ON 25 MAR 2005

E TIBOLONE/CN

L1 2 S E2-E3

FILE 'CAPLUS' ENTERED AT 12:12:50 ON 25 MAR 2005

L2 386 S L1

E TIBOLONE/BI

L3 359 S E2-E4

E TIBOLONE/CT

L4 430 S L2 OR L3

L5 147787 S STARCH? OR (POTATO STARCH?) OR (CORN STARCH?) OR (AMYLOMAIZE

L6 348947 S STABILIZER? OR (STABILIZING (W) (AGENT? OR COMPONENT? OR COMP

L7 78296 S (ASCORBYL PALMITATE?) OR "6-O-PALMITOYLASCORBIC ACID" OR "ASC

L8 61648 S LACTOSE OR DISACCHARIDE?

L9 5 S L4 AND L5 AND (L6 OR L7)

L10 3 S TIBOLONE? AND STARCH?

L11 0 S L10 NOT L9

L12 7 S L4 AND L8

L13 2 S L12 NOT L9

E HAAN P/AU

L14 3 S E3,E5,E7

E DE HAAN P/AU

L15 96 S E3-E9, E17-E18

L16 E LAMBREGTS T/AU
 1 S E4
 E HURK T/AU
 E VD HURK T/AU
 E VAN DEN HURK T/AU
 L17 1 S E4
 E MORITA R/AU
 L18 97 S E3-E6, E23
 E ROVERS A/AU
 L19 1 S E4
 E ZWINKELS J/AU
 L20 3 S E3, E8
 L21 99 S L14 OR L15
 L22 198 S L21 OR L16 OR L17 OR L18 OR L19 OR L20
 L23 4 S L22 AND TIBOLONE?

FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE, WPIDS' ENTERED AT 12:29:23 ON 25 MAR 2005

L24 8818 S TIBOLONE? OR LIVIAL? OR LIVIELLA? OR BOLTIN? OR "ORG OD14"
 L25 2399 S L24 NOT BOLTIN?
 L26 2401 S TIBOLONE? OR LIVIAL? OR LIVIELLA? OR "ORG OD14" OR "ORG OD14"
 L27 276310 S STARCH? OR (POTATO STARCH?) OR (CORN STARCH?) OR (AMYLOMAIZE
 L28 693483 S STABILIZER? OR (STABILIZING (W) (AGENT? OR COMPONENT? OR COMP
 L29 176163 S (ASCORBYL PALMITATE?) OR "6-O-PALMITOYLASCORBIC ACID" OR "ASC
 L30 139122 S LACTOSE OR DISACCHARIDE?
 L31 3 S L26 AND L27 AND (L28 OR L29)
 L32 3 DUP REM L31 (0 DUPLICATES REMOVED)
 L33 6 S TIBOLONE? AND STARCH?
 L34 5 DUP REM L33 (1 DUPLICATE REMOVED)
 L35 2 S L34 NOT L32

=> s 126 and 130
 L36 8 L26 AND L30

=> dup rem 136
 PROCESSING COMPLETED FOR L36
 L37 5 DUP REM L36 (3 DUPLICATES REMOVED)
 ANSWER '1' FROM FILE MEDLINE
 ANSWERS '2-5' FROM FILE CAPLUS

=> s 137 not 134
 L38 2 L37 NOT L34

=> d 128 1-2 ibib ed abs

L28 ANSWER 1 OF 693483 MEDLINE on STN
 ACCESSION NUMBER: 2005153240 IN-PROCESS
 DOCUMENT NUMBER: PubMed ID: 15785787
 TITLE: [Effects of psychiatric drugs on the fetus and newborn.
 Consequences of the treatment of psychiatric disorders
 during pregnancy and lactation].
 Efectos de los psicofarmacos en el feto y el recién nacido.
 Consecuencias del tratamiento de los trastornos
 psiquiátricos durante el embarazo y la lactancia.
 AUTHOR: Mazaira Silvina
 CORPORATE SOURCE: Facultad de Medicina, Universidad de Buenos Aires,
 Argentina.. smazaira@arnet.com.ar
 SOURCE: Vertex (Buenos Aires, Argentina), (2005 Jan) 16 (59) 35-42.
 Journal code: 9440528. ISSN: 0327-6139.
 PUB. COUNTRY: Argentina
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: Spanish
 FILE SEGMENT: NONMEDLINE; IN-DATA-REVIEW; IN-PROCESS; NONINDEXED;
 Priority Journals

ENTRY DATE: Entered STN: 20050324
Last Updated on STN: 20050324

ED Entered STN: 20050324
Last Updated on STN: 20050324

AB The management of mental disorders during pregnancy and the postpartum period confronts the psychiatrist to a complex clinical situation. The zero risk utopia should be changed for a more realistic approach which considers the risks of having a conservative conduct (assuming the consequences of the untreated mental disorders) or making a psychopharmacological intervention knowing the expectable effects on the fetus and the offspring. The antidepressants and the conventional antipsychotics seem to be safe drugs in the first trimester of pregnancy. The benzodiazepines and the mood **stabilizers** are linked with the appearance of teratogenic malformations after the first trimester exposure. In the present article, the pharmacokinetic peculiarities of the pregnancy and the newborn and the general considerations of the psychopharmacological management of this kind of patients are described. At last, there is a review of the literature about the effects of the different groups of psychiatric drugs on the fetal growth, their passage to maternal milk and their impact on the newborn.

L28 ANSWER 2 OF 693483 MEDLINE on STN

ACCESSION NUMBER: 2005153188 IN-PROCESS

DOCUMENT NUMBER: PubMed ID: 15647597

TITLE: Activation of Mitogen Activated Protein Kinases by PCB126 (3,3',4,4',5-Pentachlorobiphenyl) in HepG2 Cells.

AUTHOR: Song Min Ok; Freedman Jonathan H

CORPORATE SOURCE: Nicholas School of the Environment and Earth Sciences, Duke University, Durham, North Carolina 27708-0328.

SOURCE: Toxicological sciences : an official journal of the Society of Toxicology, (2005 Apr) 84 (2) 308-18. Electronic Publication: 2005-01-12.
Journal code: 9805461. ISSN: 1096-6080.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: NONMEDLINE; IN-DATA-REVIEW; IN-PROCESS; NONINDEXED;
Priority Journals

ENTRY DATE: Entered STN: 20050324
Last Updated on STN: 20050324

ED Entered STN: 20050324
Last Updated on STN: 20050324

AB Polychlorinated biphenyls (PCBs) are persistent organic pollutants. Exposure to PCB126 (3,3',4,4',5-pentachlorobiphenyl), a non-ortho-chlorinated, coplanar congener has been correlated with the production of reactive oxygen species in vivo. In this report, we show that treatment of HepG2 cells with PCB126 significantly increases oxidative-stress-responsive transcription. In addition, PCB126-induced transcription is enhanced in cells depleted of glutathione. Exposure to PCB126 induces a cellular stress response in HepG2 cells that results in a significant increase in the activity of the mitogen activated protein kinases: extracellular signal regulated kinases 1/2 and p38. PCB126 exposure also causes an increase in c-Jun phosphorylation. These results suggest a model for PCB126 toxicity in which PCB126 exposure induces oxidative stress that causes an increase in mitogen-activated protein kinase (MAPK) activities and a subsequent increase in c-Jun phosphorylation. Activation of c-Jun results in enhanced activating protein-1 (AP-1) activity, which leads to elevated expression of **antioxidant** responsive element (ARE)/AP-1-dependent genes.

=> d his

(FILE 'HOME' ENTERED AT 12:12:09 ON 25 MAR 2005)

FILE 'REGISTRY' ENTERED AT 12:12:34 ON 25 MAR 2005

L1 E TIBOLONE/CN
2 S E2-E3

FILE 'CAPLUS' ENTERED AT 12:12:50 ON 25 MAR 2005

L2 386 S L1
E TIBOLONE/BI
L3 359 S E2-E4
E TIBOLONE/CT
L4 430 S L2 OR L3
L5 147787 S STARCH? OR (POTATO STARCH?) OR (CORN STARCH?) OR (AMYLOMAIZE
L6 348947 S STABILIZER? OR (STABILIZING (W) (AGENT? OR COMPONENT? OR COMP
L7 78296 S (ASCORBYL PALMITATE?) OR "6-O-PALMITOYLASCORBIC ACID" OR "ASC
L8 61648 S LACTOSE OR DISACCHARIDE?
L9 5 S L4 AND L5 AND (L6 OR L7)
L10 3 S TIBOLONE? AND STARCH?
L11 0 S L10 NOT L9
L12 7 S L4 AND L8
L13 2 S L12 NOT L9
E HAAN P/AU
L14 3 S E3,E5,E7
E DE HAAN P/AU
L15 96 S E3-E9, E17-E18
E LAMBREGTS T/AU
L16 1 S E4
E HURK T/AU
E VD HURK T/AU
E VAN DEN HURK T/AU
L17 1 S E4
E MORITA R/AU
L18 97 S E3-E6, E23
E ROVERS A/AU
L19 1 S E4
E ZWINKELS J/AU
L20 3 S E3, E8
L21 99 S L14 OR L15
L22 198 S L21 OR L16 OR L17 OR L18 OR L19 OR L20
L23 4 S L22 AND TIBOLONE?

FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE, WPIDS' ENTERED AT 12:29:23 ON 25
MAR 2005

L24 8818 S TIBOLONE? OR LIVIAL? OR LIVIELLA? OR BOLTIN? OR "ORG OD14"
L25 2399 S L24 NOT BOLTIN?
L26 2401 S TIBOLONE? OR LIVIAL? OR LIVIELLA? OR "ORG OD14" OR "ORG OD14"
L27 276310 S STARCH? OR (POTATO STARCH?) OR (CORN STARCH?) OR (AMYLOMAIZE
L28 693483 S STABILIZER? OR (STABILIZING (W) (AGENT? OR COMPONENT? OR COMP
L29 176163 S (ASCORBYL PALMITATE?) OR "6-O-PALMITOYLASCORBIC ACID" OR "ASC
L30 139122 S LACTOSE OR DISACCHARIDE?
L31 3 S L26 AND L27 AND (L28 OR L29)
L32 3 DUP REM L31 (0 DUPLICATES REMOVED)
L33 6 S TIBOLONE? AND STARCH?
L34 5 DUP REM L33 (1 DUPLICATE REMOVED)
L35 2 S L34 NOT L32
L36 8 S L26 AND L30
L37 5 DUP REM L36 (3 DUPLICATES REMOVED)
L38 2 S L37 NOT L34

=> s "boltin"

L39 5 "BOLTIN"

=> s l39 and starch?

L40 0 L39 AND STARCH?

=> d his

(FILE 'HOME' ENTERED AT 12:12:09 ON 25 MAR 2005)

FILE 'REGISTRY' ENTERED AT 12:12:34 ON 25 MAR 2005

E TIBOLONE/CN

L1 2 S E2-E3

FILE 'CAPLUS' ENTERED AT 12:12:50 ON 25 MAR 2005

L2 386 S L1

E TIBOLONE/BI

L3 359 S E2-E4

E TIBOLONE/CT

L4 430 S L2 OR L3

L5 147787 S STARCH? OR (POTATO STARCH?) OR (CORN STARCH?) OR (AMYLOMAIZE

L6 348947 S STABILIZER? OR (STABILIZING (W) (AGENT? OR COMPONENT? OR COMP

L7 78296 S (ASCORBYL PALMITATE?) OR "6-O-PALMITOYLASCORBIC ACID" OR "ASC

L8 61648 S LACTOSE OR DISACCHARIDE?

L9 5 S L4 AND L5 AND (L6 OR L7)

L10 3 S TIBOLONE? AND STARCH?

L11 0 S L10 NOT L9

L12 7 S L4 AND L8

L13 2 S L12 NOT L9

E HAAN P/AU

L14 3 S E3,E5,E7

E DE HAAN P/AU

L15 96 S E3-E9, E17-E18

E LAMBREGTS T/AU

L16 1 S E4

E HURK T/AU

E VD HURK T/AU

E VAN DEN HURK T/AU

L17 1 S E4

E MORITA R/AU

L18 97 S E3-E6, E23

E ROVERS A/AU

L19 1 S E4

E ZWINKELS J/AU

L20 3 S E3, E8

L21 99 S L14 OR L15

L22 198 S L21 OR L16 OR L17 OR L18 OR L19 OR L20

L23 4 S L22 AND TIBOLONE?

FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE, WPIDS' ENTERED AT 12:29:23 ON 25 MAR 2005

L24 8818 S TIBOLONE? OR LIVIAL? OR LIVIELLA? OR BOLTIN? OR "ORG OD14"

L25 2399 S L24 NOT BOLTIN?

L26 2401 S TIBOLONE? OR LIVIAL? OR LIVIELLA? OR "ORG OD14" OR "ORG OD14"

L27 276310 S STARCH? OR (POTATO STARCH?) OR (CORN STARCH?) OR (AMYLOMAIZE

L28 693483 S STABILIZER? OR (STABILIZING (W) (AGENT? OR COMPONENT? OR COMP

L29 176163 S (ASCORBYL PALMITATE?) OR "6-O-PALMITOYLASCORBIC ACID" OR "ASC

L30 139122 S LACTOSE OR DISACCHARIDE?

L31 3 S L26 AND L27 AND (L28 OR L29)

L32 3 DUP REM L31 (0 DUPLICATES REMOVED)

L33 6 S TIBOLONE? AND STARCH?

L34 5 DUP REM L33 (1 DUPLICATE REMOVED)

L35 2 S L34 NOT L32

L36 8 S L26 AND L30

L37 5 DUP REM L36 (3 DUPLICATES REMOVED)

L38 2 S L37 NOT L34

L39 5 S "BOLTIN"

L40 0 S L39 AND STARCH?

=> d cost

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
CONNECT CHARGES	27.27	38.71
NETWORK CHARGES	0.90	2.70
SEARCH CHARGES	139.86	300.26
DISPLAY CHARGES	14.19	43.34
FULL ESTIMATED COST	182.22	385.01

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.19	-10.22

IN FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE, WPIDS' AT 12:38:20 ON 25 MAR 2005

=> file stngudie
 'STNGUDIE' IS NOT A VALID FILE NAME
 SESSION CONTINUES IN FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE, WPIDS'
 Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	186.22	389.01

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.19	-10.22

FILE 'STNGUIDE' ENTERED AT 12:38:54 ON 25 MAR 2005
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
 LAST RELOADED: Mar 18, 2005 (20050318/UP).

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.18	389.19

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-10.22

FILE 'REGISTRY' ENTERED AT 12:40:55 ON 25 MAR 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 MAR 2005 HIGHEST RN 847222-24-6
 DICTIONARY FILE UPDATES: 24 MAR 2005 HIGHEST RN 847222-24-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when

conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****
```

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> e potato starch/cn

```
E1      1      POTATO SPINDLE TUBER VIROID RNA-BINDING PROTEIN VIRP1 (TOMAT
O CLONE VIRP1C)/CN
E2      1      POTATO SPINDLE TUBER VIROID RNA-BINDING PROTEIN VIRP1 (TOMAT
O CLONE VIRP1D)/CN
E3      1 --> POTATO STARCH/CN
E4      1      POTATO STARCH BENZOATE ISOSTEARATE/CN
E5      1      POTATO, EXT./CN
E6      1      POTATO, EXT., SAPOND./CN
E7      1      POTATO, SOLANUM TUBEROSUM AEGROTANS, EXT./CN
E8      1      POTAVESCENT/CN
E9      1      POTB (MYCOPLASMA GALLISEPTICUM STRAIN RLOW GENE POTB)/CN
E10     1      POTB (PASTEURELLA MULTOCIDA STRAIN IL1403 CLONE PM70 GENE PO
TB)/CN
E11     1      POTB (STREPTOCOCCUS PYOGENES STRAIN MGAS10394)/CN
E12     2      POTB PROTEIN (MANNHEIMIA SUCCINICIPRODUCENS STRAIN MBEL55E G
ENE POTB)/CN
```

=> s e3

```
L41      1 "POTATO STARCH"/CN
```

=> e corn starch/cn

```
E1      1      CORN P 04/CN
E2      1      CORN PROTEIN HYDROLYZATES/CN
E3      1 --> CORN STARCH/CN
E4      1      CORN STARCH ACETATE BENZOATE/CN
E5      1      CORN STARCH-FORMALDEHYDE-HEXAMETHYLENETETRAMINE-PHENOL COPOL
YMER/CN
E6      1      CORN STARCH-HYDRAN HW 112-SUMIKAFLEX 410-YODO SOL YL 2 COPOL
YMER/CN
E7      1      CORN STEEP WATER/CN
E8      1      CORN STRAIN B73 CHROMOSOME 9S BRONZE GENE-CONTAINING REGION/
CN
E9      1      CORN SUGAR/CN
E10     1      CORN SYRUP/CN
E11     1      CORN Y/CN
E12     1      CORN, BRAN/CN
```

=> s e3

```
L42      1 "CORN STARCH"/CN
```

=> e wheat starch/cn

```
E1      1      WHEAT GERM-OIL GLYCERIDES/CN
E2      1      WHEAT GLUTEN HYDROLYZATES/CN
E3      0 --> WHEAT STARCH/CN
E4      1      WHEAT VIM/CN
```

E5	1	WHEAT, EXT./CN
E6	1	WHEAT, EXT., ET ESTER/CN
E7	1	WHEAT, EXT., HYDROLYZED/CN
E8	1	WHEAT, FLOUR/CN
E9	1	WHEAT-OIL FATTY ACIDS/CN
E10	1	WHEATLEYITE/CN
E11	1	WHEATLEYITE (NA ₂ (CU(C ₂ O ₄) ₂).2H ₂ O)/CN
E12	1	WHEATWIN1 (TRITICUM AESTIVUM VARIETY SAN PASTORE ASPARAGINE-CONTAINING ISOFORM N-TERMINAL BLOCKAGE)/CN

=> e modified starch/cn

E1	5	MODIFIED PEPTIDE (SYNTHETIC EBV FUSION INHIBITOR)/CN
E2	1	MODIFIED PROSECRETASE B (SYNTHETIC PLASMID PET11A-BACE-PRO33LYS FRAGMENT)/CN
E3	0 -->	MODIFIED STARCH/CN
E4	1	MODIFIED VASCO X2/CN
E5	1	MODIFIER A/CN
E6	1	MODIFIER KS 4930/CN
E7	1	MODIFIER OF CITRATE LYASE PROTEIN (SALMONELLA ENTERICA TYPHI MURIUM STRAIN LT2; SGSC 1412; ATCC 700720 GENE CITG)/CN
E8	1	MODIFIER OF CITRATE LYASE PROTEIN (SALMONELLA ENTERICA TYPHI MURIUM STRAIN LT2; SGSC 1412; ATCC 700720 GENE CITG2)/CN
E9	1	MODIFIER PROTEIN (YERSINIA PESTIS STRAIN CO92 GENE YPO3046)/CN
E10	1	MODIFIER PROTEIN OF MAJOR AUTOLYSIN LYTC (CWBP76) (BACILLUS LICHENIFORMIS STRAIN ATCC 14580 GENE LYTB)/CN
E11	1	MODIFIER PROTEIN OF MAJOR AUTOLYSIN LYTC (CWBP76) (BACILLUS SUBTILIS GENE LYTB)/CN
E12	1	MODIFILAN/CN

=> e agglomerated starch/cn

E1	1	AGGLOFROID 009/CN
E2	1	AGGLOFROID 313E/CN
E3	0 -->	AGGLOMERATED STARCH/CN
E4	1	AGGLOMERIN A/CN
E5	1	AGGLOMERIN B/CN
E6	1	AGGLOMERIN C/CN
E7	1	AGGLOMERIN D/CN
E8	3	AGGLOMERONE/CN
E9	1	AGGLOMERONE IMINE/CN
E10	1	AGGLOMERONE, COPPER DERIV./CN
E11	1	AGGLUCETIN/CN
E12	1	AGGLUCETIN (AGKISTRODON ACUTUS SUBUNIT A1 PRECURSOR)/C N

=> e granulated starch/cn

E1	1	GRANULAR BLUE/CN
E2	1	GRANULAR EXPLOSIVES/CN
E3	0 -->	GRANULATED STARCH/CN
E4	1	GRANULATED SUGAR/CN
E5	1	GRANULATIMIDE/CN
E6	1	GRANULATIN/CN
E7	1	GRANULATOSIDE A/CN
E8	1	GRANULATOSIDE B/CN
E9	1	GRANULE ANTIGEN PROTEIN GRA6 (TOXOPLASMA GONDII STRAIN BEVERLEY GENE GRA6)/CN
E10	1	GRANULE ANTIGEN PROTEIN GRA6 (TOXOPLASMA GONDII STRAIN CASTELLS GENE GRA6)/CN
E11	1	GRANULE ANTIGEN PROTEIN GRA6 (TOXOPLASMA GONDII STRAIN FOU GENE GRA6)/CN
E12	1	GRANULE ANTIGEN PROTEIN GRA6 (TOXOPLASMA GONDII STRAIN M7741 GENE GRA6)/CN

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	10.06	399.25
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	0.00	-10.22

FILE 'CAPLUS' ENTERED AT 12:42:18 ON 25 MAR 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Mar 2005 VOL 142 ISS 14
 FILE LAST UPDATED: 24 Mar 2005 (20050324/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 12:12:09 ON 25 MAR 2005)

FILE 'REGISTRY' ENTERED AT 12:12:34 ON 25 MAR 2005

E TIBOLONE/CN

L1 2 S E2-E3

FILE 'CAPLUS' ENTERED AT 12:12:50 ON 25 MAR 2005

L2 386 S L1

E TIBOLONE/BI

L3 359 S E2-E4

E TIBOLONE/CT

L4 430 S L2 OR L3

L5 147787 S STARCH? OR (POTATO STARCH?) OR (CORN STARCH?) OR (AMYLOMAIZE

L6 348947 S STABILIZER? OR (STABILIZING (W) (AGENT? OR COMPONENT? OR COMP

L7 78296 S (ASCORBYL PALMITATE?) OR "6-O-PALMITOYLASCORBIC ACID" OR "ASC

L8 61648 S LACTOSE OR DISACCHARIDE?

L9 5 S L4 AND L5 AND (L6 OR L7)

L10 3 S TIBOLONE? AND STARCH?

L11 0 S L10 NOT L9

L12 7 S L4 AND L8

L13 2 S L12 NOT L9

E HAAN P/AU

L14 3 S E3,E5,E7

E DE HAAN P/AU

L15 96 S E3-E9, E17-E18

E LAMBREGTS T/AU

L16 1 S E4

E HURK T/AU

E VD HURK T/AU

E VAN DEN HURK T/AU

L17 1 S E4

L18 E MORITA R/AU
 97 S E3-E6, E23
 E ROVERS A/AU
 L19 1 S E4
 E ZWINKELS J/AU
 L20 3 S E3, E8
 L21 99 S L14 OR L15
 L22 198 S L21 OR L16 OR L17 OR L18 OR L19 OR L20
 L23 4 S L22 AND TIBOLONE?

FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE, WPIDS' ENTERED AT 12:29:23 ON 25 MAR 2005

L24 8818 S TIBOLONE? OR LIVIAL? OR LIVIELLA? OR BOLTIN? OR "ORG OD14"
 L25 2399 S L24 NOT BOLTIN?
 L26 2401 S TIBOLONE? OR LIVIAL? OR LIVIELLA? OR "ORG OD14" OR "ORG OD14"
 L27 276310 S STARCH? OR (POTATO STARCH?) OR (CORN STARCH?) OR (AMYLOMAIZE
 L28 693483 S STABILIZER? OR (STABILIZING (W) (AGENT? OR COMPONENT? OR COMP
 L29 176163 S (ASCORBYL PALMITATE?) OR "6-O-PALMITOYLASCORBIC ACID" OR "ASC
 L30 139122 S LACTOSE OR DISACCHARIDE?
 L31 3 S L26 AND L27 AND (L28 OR L29)
 L32 3 DUP REM L31 (0 DUPLICATES REMOVED)
 L33 6 S TIBOLONE? AND STARCH?
 L34 5 DUP REM L33 (1 DUPLICATE REMOVED)
 L35 2 S L34 NOT L32
 L36 8 S L26 AND L30
 L37 5 DUP REM L36 (3 DUPLICATES REMOVED)
 L38 2 S L37 NOT L34
 L39 5 S "BOLTIN"
 L40 0 S L39 AND STARCH?

FILE 'STNGUIDE' ENTERED AT 12:38:54 ON 25 MAR 2005

FILE 'REGISTRY' ENTERED AT 12:40:55 ON 25 MAR 2005

E POTATO STARCH/CN
 L41 1 S E3
 E CORN STARCH/CN
 L42 1 S E3
 E WHEAT STARCH/CN
 E MODIFIED STARCH/CN
 E AGGLOMERATED STARCH/CN
 E GRANULATED STARCH/CN

FILE 'CAPLUS' ENTERED AT 12:42:18 ON 25 MAR 2005

=> s 14 and (15 or 141 or 142)

72830 L41

72830 L42

L43 6 L4 AND (L5 OR L41 OR L42)

=> d 143 1-6 ibib ed abs

L43 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:1036906 CAPLUS
 DOCUMENT NUMBER: 142:11606
 TITLE: Immediate-release pharmaceutical dosage form
 comprising a **tibolone** polymorph
 INVENTOR(S): De Haan, Pieter
 PATENT ASSIGNEE(S): Akzo Nobel N.V., Neth.
 SOURCE: PCT Int. Appl., 32 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004103378	A1	20041202	WO 2004-EP50852	20040519
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2473718	AA	20041123	CA 2004-2473718	20040519
EP 1499278	A1	20050126	EP 2004-737220	20040519
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRIORITY APPLN. INFO.:			EP 2003-101500	A 20030523
			WO 2004-EP50852	W 20040519

ED Entered STN: 03 Dec 2004

AB An immediate-release pharmaceutical dosage form comprises a **tibolone** polymorph and excipients, wherein the polymorph has a mean particle size as defined in the specification of below 22.8 µm in the dosage form. Thus, an immediate-release tablet formulation contained **tibolone** 2.5, **potato starch** 10, ascorbyl palmitate 0.2, Mg stearate 0.5, and lactose 86.8 mg.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:453011 CAPLUS

DOCUMENT NUMBER: 140:429053

TITLE: Pharmaceutical tablets containing **tibolone** and a coating

INVENTOR(S): De Haan, Pieter; Van Lare, Cornelis Elisabeth Johannus

PATENT ASSIGNEE(S): Akzo Nobel N.V., Neth.

SOURCE: PCT Int. Appl., 20 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004045587	A1	20040603	WO 2003-EP50829	20031113
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			EP 2002-79920	A 20021120
			US 2002-427740P	P 20021120

ED Entered STN: 04 Jun 2004

AB The present invention relates to a stabilized pharmaceutical tablet comprising an amount of from 0.1 to 10% by weight of **tibolone** provided with a coating, such as a film coating, a sugar coating, a sugar

film coating or a wrap coating. The invention further relates to the use of a coating for stabilizing a pharmaceutical tablet comprising **tibolone**. Preferably, the coating is a sugar coating or a sugar film coating. Preferably, the sugar comprises sucrose. These tablets were shown to have a lower amount of OM38, i.e. an isomerization degradation product of **tibolone**, after storage as compared to uncoated **tibolone** tablets. For example, a tablet was formulated containing **tibolone**, basic granulates (**starch**/lactose), ascorbyl palmitate, and Mg stearate and a film-coated with a composition containing hydroxypropyl Me cellulose, polyethylene glycol, titania, and talc, further coated with a composition containing arabic gum, saccharose, Ca carbonate, talc, titania, polyethylene glycol, glucose syrup, glycerol, and china clay.

L43 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:708947 CAPLUS
DOCUMENT NUMBER: 129:335779
TITLE: Stabilized **tibolone** compositions
INVENTOR(S): Haan De, Pieter; Rovers, Adrianus Cornelis Petrus; Lambregts-De Hurk, Theodora Antonia Maria; Zwinkels, Jocominus Antonius Maria; Morita, Ryoichi
PATENT ASSIGNEE(S): Akzo Nobel N.V., Neth.
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9847517	A1	19981029	WO 1998-EP2361	19980420
W: AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, ID, IS, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
IL 123984	A1	20040927	IL 1998-123984	19980407
ZA 9803169	A	19981020	ZA 1998-3169	19980415
CA 2288070	AA	19981029	CA 1998-2288070	19980420
AU 9880146	A1	19981113	AU 1998-80146	19980420
AU 742037	B2	20011213		
EP 975348	A1	20000202	EP 1998-928214	19980420
EP 975348	B1	20041110		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
TR 9902530	T2	20000522	TR 1999-9902530	19980420
BR 9809268	A	20000627	BR 1998-9268	19980420
NZ 338028	A	20011026	NZ 1998-338028	19980420
RU 2207133	C2	20030627	RU 1999-121407	19980420
AT 281836	E	20041115	AT 1998-928214	19980420
JP 10316573	A2	19981202	JP 1998-112312	19980422
TW 570798	B	20040111	TW 1998-87107211	19980511
US 2001005513	A1	20010628	US 1999-403139	19991014
US 6399594	B2	20020604		
NO 9905127	A	19991021	NO 1999-5127	19991021
MX 9909676	A	20000331	MX 1999-9676	19991021
US 6514958	B1	20030204	US 2002-117899	20020408
US 2003119801	A1	20030626	US 2002-303494	20021125
US 2004142030	A1	20040722	US 2004-754685	20040108
US 2004142028	A1	20040722	US 2004-754732	20040108

US 2004142031 A1 20040722 US 2004-754733 20040108
 PRIORITY APPLN. INFO.: EP 1997-201180 A 19970422
 WO 1998-EP2361 W 19980420
 US 1999-403139 A1 19991014
 US 2002-117899 A1 20020408
 US 2002-303494 B1 20021125

ED Entered STN: 09 Nov 1998

AB The invention pertains to a pharmaceutical dosage unit, such as a tablet or a capsule, comprising an effective amount of **tibolone** (0.1-10 % by weight) and a **starch**-containing pharmaceutically acceptable carrier (also denoted as basic granules), wherein the carrier contains 10-100% by weight of the **starch**. Thus, a more stable **tibolone** formulation is obtained, allowing dry storage and lower doses of active ingredient. Thus, basic granules contained **tibolone** 0.3, HPC 1.95, **corn starch** 32.5, Mg stearate 0.325, and lactose to 65 mg.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:313906 CAPLUS

DOCUMENT NUMBER: 124:352708

TITLE: Solid pharmaceutical composition comprising an excipient capable of binding water

INVENTOR(S): De Haan, Pieter; Poels-Janssen, Henrika Gerardina Maria

PATENT ASSIGNEE(S): Akzo Nobel N.V., Neth.

SOURCE: Eur. Pat. Appl., 9 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 707848	A1	19960424	EP 1995-202770	19951013
EP 707848	B1	20020109		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE				
CA 2159419	AA	19960418	CA 1995-2159419	19950928
IL 115445	A1	19990817	IL 1995-115445	19950928
BR 9504400	A	19970527	BR 1995-4400	19951013
AT 211647	E	20020115	AT 1995-202770	19951013
PT 707848	T	20020628	PT 1995-202770	19951013
ES 2171498	T3	20020916	ES 1995-202770	19951013
FI 9504905	A	19960418	FI 1995-4905	19951016
AU 9534267	A1	19960502	AU 1995-34267	19951016
AU 688581	B2	19980312		
CN 1130064	A	19960904	CN 1995-116176	19951016
CN 1112185	B	20030625		
HU 75247	A2	19970528	HU 1995-2985	19951016
HU 221427	B	20021028		
RU 2152802	C2	20000720	RU 1995-118099	19951016
JP 08268914	A2	19961015	JP 1995-268772	19951017
US 6187339	B1	20010213	US 1995-544042	19951017
HK 1001886	A1	20020531	HK 1998-101017	19980211

PRIORITY APPLN. INFO.: EP 1994-203017 A 19941017

ED Entered STN: 30 May 1996

AB The invention concerns a solid pharmaceutical composition comprising less than 7% by weight of an oil or oily substance, a low dosage active ingredient, and a water-insol. noncrosslinked polymeric excipient capable of binding water and having a mean particle size greater than 150 µm. The invention offers a solution for obtaining drug-loaded carrier particles without the need of a granulation step by using the solid composition The composition can

be

obtained by a simple procedure comprising mixing the water-insol. noncrosslinked polymeric excipient capable of binding water, preferably cellulose or **starch**, and the active ingredient, which is dissolved or dispersed in an oil or an oily substance, in an aqueous dispersion thereof, or in water. A tablet contained desogestrel 150, ethinyl estradiol 30 µg, Miglyol 812 1.3, water 3.68, Avicel PH-200 58.99, Me cellulose 0.07, and silica 0.81 mg.

L43 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1994:686615 CAPLUS
DOCUMENT NUMBER: 121:286615
TITLE: Pharmaceutical compositions containing pregnane derivatives for the treatment of tumors.
INVENTOR(S): Deckers, Godefridus Hermanus Johanna; Kloosterboer, Helenius Jan
PATENT ASSIGNEE(S): Akazo Nobel N.V., Neth.
SOURCE: Eur. Pat. Appl., 9 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 613687	A1	19940907	EP 1994-200523	19940302
EP 613687	B1	19990602		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CA 2116829	AA	19940906	CA 1994-2116829	19940302
CA 2116829	C	20040914		
AU 9457542	A1	19940908	AU 1994-57542	19940302
AU 671706	B2	19960905		
ZA 9401464	A	19940927	ZA 1994-1464	19940302
AT 180669	E	19990615	AT 1994-200523	19940302
ES 2134313	T3	19991001	ES 1994-200523	19940302
NO 9400777	A	19940906	NO 1994-777	19940304
JP 07002673	A2	19950106	JP 1994-34540	19940304
JP 3391539	B2	20030331		
US 5512556	A	19960430	US 1994-358639	19941219
PRIORITY APPLN. INFO.:			EP 1993-200631	A 19930305
			US 1994-206994	B1 19940307

OTHER SOURCE(S): MARPAT 121:286615

ED Entered STN: 10 Dec 1994

AB Pharmaceutical compns. containing pregnane derivs. (Markush structure given) are useful for prevention or treatment of tumors. A twice daily dose of 1 mg/kg (7α,17α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one (I) inhibited the tumor growth in rats up to .apprx.70%. A tablet contained I 2.5, **starch** 10, ascorbyl palmitate 0.2, Mg stearate 0.5, and lactose q.s. to 100 mg.

L43 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1991:214521 CAPLUS
DOCUMENT NUMBER: 114:214521
TITLE: Pharmaceutical composition containing the pure crystalline forms of (7α, 17α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one
INVENTOR(S): Sas, G. A. J. M. T.; Van Doornum, E. M.
PATENT ASSIGNEE(S): AKZO N. V., Neth.
SOURCE: Eur. Pat. Appl., 13 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 389035	A1	19900926	EP 1990-200574	19900312
EP 389035	B1	19931215		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE				
ZA 9001674	A	19901228	ZA 1990-1674	19900305
CA 2011452	C	19990525	CA 1990-2011452	19900305
AT 98490	E	19940115	AT 1990-200574	19900312
ES 2062292	T3	19941216	ES 1990-200574	19900312
JP 03047195	A2	19910228	JP 1990-63921	19900314
JP 3139709	B2	20010305		
JP 2001139473	A2	20010522	JP 2000-316716	19900314
US 5037817	A	19910806	US 1990-494089	19900315
AU 9051394	A1	19900920	AU 1990-51394	19900316
AU 625083	B2	19920702		
FI 94865	B	19950731	FI 1990-1328	19900316
FI 94865	C	19951110		
KR 183401	B1	19990501	KR 1990-3574	19900317
PRIORITY APPLN. INFO.:				
			NL 1989-673	A 19890318
			EP 1990-200574	A 19900312
			JP 1990-63921	A3 19900314

ED Entered STN: 31 May 1991

AB Pure monoclinic or triclinic (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one (I) are more suitable for pharmaceutical compns. than the polymorphous I. A solution of 1 kg I in 23 L acetone containing

6 mL pyridine, was poured, under N, in 25 L water, followed by cooling to 0-5°, to crystallize monoclinic I (crystalline structure and x-ray diffraction spectrum given). Tablets comprised monoclinic I 2.5, starch 10, ascorbyl palmitate 0.2, Mg stearate 0.5, and lactose to 100 mg/tablet. I forms are useful for treating menopausal disorders, for immunomodulation, and for treating osteoporosis (no data).

=> d his

(FILE 'HOME' ENTERED AT 12:12:09 ON 25 MAR 2005)

FILE 'REGISTRY' ENTERED AT 12:12:34 ON 25 MAR 2005

E TIBOLONE/CN

L1 2 S E2-E3

FILE 'CAPLUS' ENTERED AT 12:12:50 ON 25 MAR 2005

L2 386 S L1

E TIBOLONE/BI

L3 359 S E2-E4

E TIBOLONE/CT

L4 430 S L2 OR L3

L5 147787 S STARCH? OR (POTATO STARCH?) OR (CORN STARCH?) OR (AMYLOMAIZE

L6 348947 S STABILIZER? OR (STABILIZING (W) (AGENT? OR COMPONENT? OR COMP

L7 78296 S (ASCORBYL PALMITATE?) OR "6-O-PALMITOYLASCORBIC ACID" OR "ASC

L8 61648 S LACTOSE OR DISACCHARIDE?

L9 5 S L4 AND L5 AND (L6 OR L7)

L10 3 S TIBOLONE? AND STARCH?

L11 0 S L10 NOT L9

L12 7 S L4 AND L8

L13 2 S L12 NOT L9

E HAAN P/AU

L14 3 S E3,E5,E7

E DE HAAN P/AU

L15 96 S E3-E9, E17-E18

E LAMBREGTS T/AU

L16 1 S E4

E HURK T/AU
 E VD HURK T/AU
 E VAN DEN HURK T/AU
 L17 1 S E4
 E MORITA R/AU
 L18 97 S E3-E6, E23
 E ROVERS A/AU
 L19 1 S E4
 E ZWINKELS J/AU
 L20 3 S E3, E8
 L21 99 S L14 OR L15
 L22 198 S L21 OR L16 OR L17 OR L18 OR L19 OR L20
 L23 4 S L22 AND TIBOLONE?

FILE 'MEDLINE,' BIOSIS, CAPLUS, EMBASE, WPIDS' ENTERED AT 12:29:23 ON 25 MAR 2005

L24 8818 S TIBOLONE? OR LIVIAL? OR LIVIELLA? OR BOLTIN? OR "ORG OD14"
 L25 2399 S L24 NOT BOLTIN?
 L26 2401 S TIBOLONE? OR LIVIAL? OR LIVIELLA? OR "ORG OD14" OR "ORG OD14"
 L27 276310 S STARCH? OR (POTATO STARCH?) OR (CORN STARCH?) OR (AMYLOMAIZE
 L28 693483 S STABILIZER? OR (STABILIZING (W) (AGENT? OR COMPONENT? OR COMP
 L29 176163 S (ASCORBYL PALMITATE?) OR "6-O-PALMITOYLASCORBIC ACID" OR "ASC
 L30 139122 S LACTOSE OR DISACCHARIDE?
 L31 3 S L26 AND L27 AND (L28 OR L29)
 L32 3 DUP REM L31 (0 DUPLICATES REMOVED)
 L33 6 S TIBOLONE? AND STARCH?
 L34 5 DUP REM L33 (1 DUPLICATE REMOVED)
 L35 2 S L34 NOT L32
 L36 8 S L26 AND L30
 L37 5 DUP REM L36 (3 DUPLICATES REMOVED)
 L38 2 S L37 NOT L34
 L39 5 S "BOLTIN"
 L40 0 S L39 AND STARCH?

FILE 'STNGUIDE' ENTERED AT 12:38:54 ON 25 MAR 2005

FILE 'REGISTRY' ENTERED AT 12:40:55 ON 25 MAR 2005

E POTATO STARCH/CN
 L41 1 S E3
 E CORN STARCH/CN
 L42 1 S E3
 E WHEAT STARCH/CN
 E MODIFIED STARCH/CN
 E AGGLOMERATED STARCH/CN
 E GRANULATED STARCH/CN

FILE 'CAPLUS' ENTERED AT 12:42:18 ON 25 MAR 2005

L43 6 S L4 AND (L5 OR L41 OR L42)

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	17.25	416.50
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.38	-14.60

FILE 'REGISTRY' ENTERED AT 12:43:55 ON 25 MAR 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file

provided by InfoChem.

STRUCTURE FILE UPDATES: 24 MAR 2005 HIGHEST RN 847222-24-6
DICTIONARY FILE UPDATES: 24 MAR 2005 HIGHEST RN 847222-24-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> e lactose/cn

E1	1	LACTOSAZONE/CN
E2	1	LACTOSCATONE/CN
E3	1 -->	LACTOSE/CN
E4	1	LACTOSE 100M/CN
E5	1	LACTOSE 2',6'-DIPALMITATE/CN
E6	1	LACTOSE 2'-PALMITATE/CN
E7	1	LACTOSE 2,4-DINITROPHENYLHYDRAZONE/CN
E8	1	LACTOSE 3'-PHOSPHATE/CN
E9	1	LACTOSE 4'-PHOSPHATE/CN
E10	1	LACTOSE 4-NITROPHENYLHYDRAZONE/CN
E11	1	LACTOSE 6'-PALMITATE/CN
E12	1	LACTOSE 6'-PHOSPHATE/CN

=> s e3

L44 1 LACTOSE/CN

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	5.03	421.53
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-14.60

FILE 'CAPLUS' ENTERED AT 12:44:08 ON 25 MAR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Mar 2005 VOL 142 ISS 14
FILE LAST UPDATED: 24 Mar 2005 (20050324/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 144

L45 23757 L44

=> d his

(FILE 'HOME' ENTERED AT 12:12:09 ON 25 MAR 2005)

FILE 'REGISTRY' ENTERED AT 12:12:34 ON 25 MAR 2005

E TIBOLONE/CN

L1 2 S E2-E3

FILE 'CAPLUS' ENTERED AT 12:12:50 ON 25 MAR 2005

L2 386 S L1

E TIBOLONE/BI

L3 359 S E2-E4

E TIBOLONE/CT

L4 430 S L2 OR L3

L5 147787 S STARCH? OR (POTATO STARCH?) OR (CORN STARCH?) OR (AMYLOMAIZE

L6 348947 S STABILIZER? OR (STABILIZING (W) (AGENT? OR COMPONENT? OR COMP

L7 78296 S (ASCORBYL PALMITATE?) OR "6-O-PALMITOYLASCORBIC ACID" OR "ASC

L8 61648 S LACTOSE OR DISACCHARIDE?

L9 5 S L4 AND L5 AND (L6 OR L7)

L10 3 S TIBOLONE? AND STARCH?

L11 0 S L10 NOT L9

L12 7 S L4 AND L8

L13 2 S L12 NOT L9

E HAAN P/AU

L14 3 S E3,E5,E7

E DE HAAN P/AU

L15 96 S E3-E9, E17-E18

E LAMBREGTS T/AU

L16 1 S E4

E HURK T/AU

E VD HURK T/AU

E VAN DEN HURK T/AU

L17 1 S E4

E MORITA R/AU

L18 97 S E3-E6, E23

E ROVERS A/AU

L19 1 S E4

E ZWINKELS J/AU

L20 3 S E3, E8

L21 99 S L14 OR L15

L22 198 S L21 OR L16 OR L17 OR L18 OR L19 OR L20

L23 4 S L22 AND TIBOLONE?

FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE, WPIDS' ENTERED AT 12:29:23 ON 25 MAR 2005

L24 8818 S TIBOLONE? OR LIVIAL? OR LIVIELLA? OR BOLTIN? OR "ORG OD14"

L25 2399 S L24 NOT BOLTIN?

L26 2401 S TIBOLONE? OR LIVIAL? OR LIVIELLA? OR "ORG OD14" OR "ORG OD14"

L27 276310 S STARCH? OR (POTATO STARCH?) OR (CORN STARCH?) OR (AMYLOMAIZE

L28 693483 S STABILIZER? OR (STABILIZING (W) (AGENT? OR COMPONENT? OR COMP

L29 176163 S (ASCORBYL PALMITATE?) OR "6-O-PALMITOYLASCORBIC ACID" OR "ASC
 L30 139122 S LACTOSE OR DISACCHARIDE?
 L31 3 S L26 AND L27 AND (L28 OR L29)
 L32 3 DUP REM L31 (0 DUPLICATES REMOVED)
 L33 6 S TIBOLONE? AND STARCH?
 L34 5 DUP REM L33 (1 DUPLICATE REMOVED)
 L35 2 S L34 NOT L32
 L36 8 S L26 AND L30
 L37 5 DUP REM L36 (3 DUPLICATES REMOVED)
 L38 2 S L37 NOT L34
 L39 5 S "BOLTIN"
 L40 0 S L39 AND STARCH?

FILE 'STNGUIDE' ENTERED AT 12:38:54 ON 25 MAR 2005

FILE 'REGISTRY' ENTERED AT 12:40:55 ON 25 MAR 2005

E POTATO STARCH/CN
 L41 1 S E3
 E CORN STARCH/CN
 L42 1 S E3
 E WHEAT STARCH/CN
 E MODIFIED STARCH/CN
 E AGGLOMERATED STARCH/CN
 E GRANULATED STARCH/CN

FILE 'CAPLUS' ENTERED AT 12:42:18 ON 25 MAR 2005

L43 6 S L4 AND (L5 OR L41 OR L42)

FILE 'REGISTRY' ENTERED AT 12:43:55 ON 25 MAR 2005

E LACTOSE/CN
 L44 1 S E3

FILE 'CAPLUS' ENTERED AT 12:44:08 ON 25 MAR 2005

L45 23757 S L44

=> s 14 and 145

L46 0 L4 AND L45

=> s tibolone and starch?

358 TIBOLONE
 1 TIBOLONES
 358 TIBOLONE
 (TIBOLONE OR TIBOLONES)

147702 STARCH?

L47 3 TIBOLONE AND STARCH?

=> s 147 not 143

L48 0 L47 NOT L43

=> d his

(FILE 'HOME' ENTERED AT 12:12:09 ON 25 MAR 2005)

FILE 'REGISTRY' ENTERED AT 12:12:34 ON 25 MAR 2005

E TIBOLONE/CN
 L1 2 S E2-E3

FILE 'CAPLUS' ENTERED AT 12:12:50 ON 25 MAR 2005

L2 386 S L1
 E TIBOLONE/BI
 L3 359 S E2-E4
 E TIBOLONE/CT
 L4 430 S L2 OR L3
 L5 147787 S STARCH? OR (POTATO STARCH?) OR (CORN STARCH?) OR (AMYLOMAIZE

L6 348947 S STABILIZER? OR (STABILIZING (W) (AGENT? OR COMPONENT? OR COMP
 L7 78296 S (ASCORBYL PALMITATE?) OR "6-O-PALMITOYLASCORBIC ACID" OR "ASC
 L8 61648 S LACTOSE OR DISACCHARIDE?
 L9 5 S L4 AND L5 AND (L6 OR L7)
 L10 3 S TIBOLONE? AND STARCH?
 L11 0 S L10 NOT L9
 L12 7 S L4 AND L8
 L13 2 S L12 NOT L9
 E HAAN P/AU
 L14 3 S E3,E5,E7
 E DE HAAN P/AU
 L15 96 S E3-E9, E17-E18
 E LAMBREGTS T/AU
 L16 1 S E4
 E HURK T/AU
 E VD HURK T/AU
 E VAN DEN HURK T/AU
 L17 1 S E4
 E MORITA R/AU
 L18 97 S E3-E6, E23
 E ROVERS A/AU
 L19 1 S E4
 E ZWINKELS J/AU
 L20 3 S E3, E8
 L21 99 S L14 OR L15
 L22 198 S L21 OR L16 OR L17 OR L18 OR L19 OR L20
 L23 4 S L22 AND TIBOLONE?

FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE, WPIDS' ENTERED AT 12:29:23 ON 25
 MAR 2005

L24 8818 S TIBOLONE? OR LIVIAL? OR LIVIELLA? OR BOLTIN? OR "ORG OD14"
 L25 2399 S L24 NOT BOLTIN?
 L26 2401 S TIBOLONE? OR LIVIAL? OR LIVIELLA? OR "ORG OD14" OR "ORG OD14"
 L27 276310 S STARCH? OR (POTATO STARCH?) OR (CORN STARCH?) OR (AMYLOMAIZE
 L28 693483 S STABILIZER? OR (STABILIZING (W) (AGENT? OR COMPONENT? OR COMP
 L29 176163 S (ASCORBYL PALMITATE?) OR "6-O-PALMITOYLASCORBIC ACID" OR "ASC
 L30 139122 S LACTOSE OR DISACCHARIDE?
 L31 3 S L26 AND L27 AND (L28 OR L29)
 L32 3 DUP REM L31 (0 DUPLICATES REMOVED)
 L33 6 S TIBOLONE? AND STARCH?
 L34 5 DUP REM L33 (1 DUPLICATE REMOVED)
 L35 2 S L34 NOT L32
 L36 8 S L26 AND L30
 L37 5 DUP REM L36 (3 DUPLICATES REMOVED)
 L38 2 S L37 NOT L34
 L39 5 S "BOLTIN"
 L40 0 S L39 AND STARCH?

FILE 'STNGUIDE' ENTERED AT 12:38:54 ON 25 MAR 2005

FILE 'REGISTRY' ENTERED AT 12:40:55 ON 25 MAR 2005

E POTATO STARCH/CN
 L41 1 S E3
 E CORN STARCH/CN
 L42 1 S E3
 E WHEAT STARCH/CN
 E MODIFIED STARCH/CN
 E AGGLOMERATED STARCH/CN
 E GRANULATED STARCH/CN

FILE 'CAPLUS' ENTERED AT 12:42:18 ON 25 MAR 2005

L43 6 S L4 AND (L5 OR L41 OR L42)

FILE 'REGISTRY' ENTERED AT 12:43:55 ON 25 MAR 2005

L44 E LACTOSE/CN
1 S E3

FILE 'CAPLUS' ENTERED AT 12:44:08 ON 25 MAR 2005
L45 23757 S L44
L46 0 S L4 AND L45
L47 3 S TIBOLONE AND STARCH?
L48 0 S L47 NOT L43

=> save
ENTER L#, L# RANGE, ALL, OR (END):all
ENTER NAME OR (END):l10754733/l
L# LIST L1-L48 HAS BEEN SAVED AS 'L10754733/L'

	SINCE FILE	TOTAL
	ENTRY	SESSION
CONNECT CHARGES	0.78	45.71
NETWORK CHARGES	0.12	3.42
SEARCH CHARGES	3.78	317.84
DISPLAY CHARGES	0.00	59.24
	-----	-----
FULL ESTIMATED COST	4.68	426.21
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-14.60

IN FILE 'CAPLUS' AT 12:45:05 ON 25 MAR 2005

=> d his

(FILE 'HOME' ENTERED AT 12:12:09 ON 25 MAR 2005)

FILE 'REGISTRY' ENTERED AT 12:12:34 ON 25 MAR 2005
E TIBOLONE/CN

L1 2 S E2-E3

FILE 'CAPLUS' ENTERED AT 12:12:50 ON 25 MAR 2005

L2 386 S L1
E TIBOLONE/BI
L3 359 S E2-E4
E TIBOLONE/CT
L4 430 S L2 OR L3
L5 147787 S STARCH? OR (POTATO STARCH?) OR (CORN STARCH?) OR (AMYLOMAIZE
L6 348947 S STABILIZER? OR (STABILIZING (W) (AGENT? OR COMPONENT? OR COMP
L7 78296 S (ASCORBYL PALMITATE?) OR "6-O-PALMITOYLASCORBIC ACID" OR "ASC
L8 61648 S LACTOSE OR DISACCHARIDE?
L9 5 S L4 AND L5 AND (L6 OR L7)
L10 3 S TIBOLONE? AND STARCH?
L11 0 S L10 NOT L9
L12 7 S L4 AND L8
L13 2 S L12 NOT L9
E HAAN P/AU
L14 3 S E3,E5,E7
E DE HAAN P/AU
L15 96 S E3-E9, E17-E18
E LAMBREGTS T/AU
L16 1 S E4
E HURK T/AU
E VD HURK T/AU
E VAN DEN HURK T/AU
L17 1 S E4

L18 E MORITA R/AU
 97 S E3-E6, E23
 E ROVERS A/AU
 L19 1 S E4
 E ZWINKELS J/AU
 L20 3 S E3, E8
 L21 99 S L14 OR L15
 L22 198 S L21 OR L16 OR L17 OR L18 OR L19 OR L20
 L23 4 S L22 AND TIBOLONE?

FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE, WPIDS' ENTERED AT 12:29:23 ON 25 MAR 2005

L24 8818 S TIBOLONE? OR LIVIAL? OR LIVIELLA? OR BOLTIN? OR "ORG OD14"
 L25 2399 S L24 NOT BOLTIN?
 L26 2401 S TIBOLONE? OR LIVIAL? OR LIVIELLA? OR "ORG OD14" OR "ORG OD14"
 L27 276310 S STARCH? OR (POTATO STARCH?) OR (CORN STARCH?) OR (AMYLOMAIZE
 L28 693483 S STABILIZER? OR (STABILIZING (W) (AGENT? OR COMPONENT? OR COMP
 L29 176163 S (ASCORBYL PALMITATE?) OR "6-O-PALMITOYLASCORBIC ACID" OR "ASC
 L30 139122 S LACTOSE OR DISACCHARIDE?
 L31 3 S L26 AND L27 AND (L28 OR L29)
 L32 3 DUP REM L31 (0 DUPLICATES REMOVED)
 L33 6 S TIBOLONE? AND STARCH?
 L34 5 DUP REM L33 (1 DUPLICATE REMOVED)
 L35 2 S L34 NOT L32
 L36 8 S L26 AND L30
 L37 5 DUP REM L36 (3 DUPLICATES REMOVED)
 L38 2 S L37 NOT L34
 L39 5 S "BOLTIN"
 L40 0 S L39 AND STARCH?

FILE 'STNGUIDE' ENTERED AT 12:38:54 ON 25 MAR 2005

FILE 'REGISTRY' ENTERED AT 12:40:55 ON 25 MAR 2005

E POTATO STARCH/CN
 L41 1 S E3
 E CORN STARCH/CN
 L42 1 S E3
 E WHEAT STARCH/CN
 E MODIFIED STARCH/CN
 E AGGLOMERATED STARCH/CN
 E GRANULATED STARCH/CN

FILE 'CAPLUS' ENTERED AT 12:42:18 ON 25 MAR 2005

L43 6 S L4 AND (L5 OR L41 OR L42)

FILE 'REGISTRY' ENTERED AT 12:43:55 ON 25 MAR 2005

E LACTOSE/CN
 L44 1 S E3

FILE 'CAPLUS' ENTERED AT 12:44:08 ON 25 MAR 2005

L45 23757 S L44
 L46 0 S L4 AND L45
 L47 3 S TIBOLONE AND STARCH?
 L48 0 S L47 NOT L43
 SAVE ALL L10754733/L